

GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ANTAGONISTS

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Application No. 63/395,783 filed on August 5, 2022, the disclosure of which is expressly incorporated
5 herein.

INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED
ELECTRONICALLY

The instant application contains a Sequence Listing which has been submitted
10 electronically in XML file format and is hereby incorporated by reference in its
entirety. Said XML copy, created on August 1, 2023, is named 32993-392614.2_SL.xml
and is 281 kilobytes in size.

BACKGROUND

15 Glucagon-like peptide-1 (GLP-1) plays an important role in regulating blood
glucose levels in humans. Its actions include stimulation of insulin synthesis and
secretion, inhibition of glucagon secretion, and inhibition of food intake. Normally, the
body maintains the concentration of glucose in the blood within a range of about 70 to 110
milligrams per deciliter (mg/dL), or 3.9 to 6.1 millimoles per liter (mmol/L). However,
20 conditions can arise where glucose level becomes too low, leading to hypoglycemia.
Hypoglycemia is most often caused by drugs taken to control diabetes. Much fewer
common causes of hypoglycemia are referred to herein as “atypical hypoglycemia”, and
can occur independent of exogenous insulin administration.

Atypical hypoglycemia can occur in people who drink heavily without eating, as
25 alcohol can block the formation of glucose in the liver. In addition, people with advanced
liver disease, such as viral hepatitis, cirrhosis, or cancer of the liver may not be able to
store and produce sufficient glucose. Atypical hypoglycemia can also result in infants and
children that have a congenital mutation that render them hyperinsulinemic.

More recently, over the course of the last decade there has been an increased
30 awareness that atypical hypoglycemia is a complication that can arise after surgical
procedures performed for the purpose of reversing extreme forms of obesity. Some
patients (less than 10%) receiving Roux-en-Y gastric bypass (RYGB) surgeries
subsequently develop hyperinsulinemic hypoglycemia, wherein blood glucose
concentrations can become low enough (20-40 mg/dL) to cause seizures, altered mental
35 status, loss of consciousness, cognitive dysfunction, disability, and death.

One approach to treating hyperinsulinemic-induced hypoglycemia is to administer

a GLP-1 receptor antagonist. Such peptide antagonists block the ability of inappropriately elevated concentrations of plasma GLP-1 to stimulate insulin secretion, and function to normalize plasma glucose and reduce risk of cognitive impairment, vascular disease and potentially sudden death in patients experiencing atypical hypoglycemia.

5 Exendin-4 (SEQ ID NO: 1) is a 39 amino acid agonist of the glucagon-like peptide 1 (GLP-1) receptor. Exendin-4 is present in the saliva of the Gila monster, *Heloderma suspectum*. Ex-4 (9-39)a (SEQ ID NO: 2) is an N-terminal truncated derivative of Exendin-4 that is known to function as a GLP-1 receptor antagonist. However, Ex-4 (9-39)a suffers from two notable limitations regarding its potential use to
10 treat chronic atypical hypoglycemia: its nonhuman amino acid sequence, and its relatively short *in vivo* duration of action.

 In accordance with one embodiment of the present disclosure a set of novel optimized GLP-1 antagonists are provided for use as drug candidates in treatment of atypical hypoglycemia, including hyperinsulinemic induced hypoglycemia resulting after
15 post-bariatric surgical procedures or resulting from congenital mutations.

SUMMARY

 As disclosed herein compositions and methods are provided for treating patients experiencing atypical hypoglycemia, and more particularly in one embodiment, treating
20 patients who experience hyperinsulinemia induced hypoglycemia. In accordance with one embodiment compositions and methods are provided for treating hyperinsulinemia induced hypoglycemia resulting after post-bariatric surgery. In one embodiment the method comprises the administration of a glucagon-like peptide-1 receptor antagonist (GLP1RA) in an amount effective to elevate blood glucose levels and alleviate associated
25 acute symptoms and chronic outcomes associated with hypoglycemia.

 In accordance with one embodiment a GLP-1 receptor antagonist peptide is provided comprising the amino acid sequence

R₁₀-DX₁₀X₁₁RYLX₁₅X₁₆QAVREFX₂₃EWLVRRGGPSSGAPPPSX₄₀R₂₀ (SEQ ID NO: 5), wherein

30 X₁₀ is Trp, dTrp or Val; X₁₁ is Trp, dTrp or Ser; X₁₅ is Glu or dGlu

X₁₆ is Trp, dTrp, dGlu or Glu; X₂₃ is Ile or dIle;

X₄₀ is absent or an acylated amino acid,

R₁₀ is NH₂, -CO(CH₂)₁₄₋₂₀CH₃ or -CO(CH₂)₁₄₋₂₀COOH and

R₂₀ is COOH or CONH₂, optionally wherein the peptide comprises one or more
35 substitutions of Aib at any of positions 16, 18, 19, 24, 26 or 28, relative to the native Exendin4 sequence (SEQ ID NO: 1), or optionally a substitution of Lys at position 12, relative to the native Exendin4 sequence (SEQ ID NO: 1), optionally with the proviso that

when one of X₁₀ or X₁₁ is Trp or dTrp, the other is not Trp or dTrp, optionally with the proviso that R₁₀ is not NH₂, when X₄₀ is absent. In one embodiment a GLP-1 receptor antagonist of SEQ ID NO: 5 is provided wherein X₄₀ is an acylated Lys, wherein the acyl group of the acylated Lys is a C16-C18 acid or diacid, optionally linked via a spacer to the Lys side chain.

In one embodiment a GLP-1 receptor antagonist is provided, wherein the antagonist comprises the amino acid sequence of

R₁₀-DX₁₀X₁₁X₁₂YLX₁₅X₁₆QAVREFX₂₃X₂₄WLVRRGGPSSGAPPPS (SEQ ID NO: 98);

wherein

X₁₀ is Trp, dTrp or Val;

X₁₁ is Trp, dTrp or Ser; X₁₂ is Arg, Lys or Ser X₁₅ is Glu or dGlu

X₁₆ is Trp, dTrp, dGlu or Glu; X₂₃ is Ile or dIle;

X₂₄ is Ala or Glu; and

R₁₀ is -CO(CH₂)₁₄₋₂₀CH₃ or -CO(CH₂)₁₄₋₂₀COOH.

In accordance with one embodiment a GLP-1 receptor antagonist peptide is provided having the amino acid sequence of

DVWRYLX₁₅EQAVREFIEWLVRRGGPSSGAPPPSX₄₀R₂₀ (SEQ ID NO: 96),

wherein

X₁₅ is dGlu;

X₄₀ is an acylated Lys and R₂₀ is COOH or CONH₂, wherein the acyl group of the acylated Lys is a C16-C18 acid or diacid, optionally linked via a spacer to the Lys side chain. In one embodiment the spacer comprises a minipep or a gamma glutamic acid subunit or any multiple or combination of such minipep or gamma Glu molecules. In one embodiment the peptide of SEQ ID NO: 96 is modified with 1, 2 or 3 amino acid substitutions, including for example, substitution with amino isobutyric acid (Aib) at one or more of positions 16, 18, 19, 24, 26 or 28, relative to the native Exendin4 sequence of SEQ ID NO: 1; or substitution of Lys at position 12.

In accordance with one embodiment a GLP-1 receptor antagonist peptide is provided comprising the amino acid sequence

DX₁₀X₁₁RYLX₁₅X₁₆QAVREFX₂₃EWLVRRGGPSSGAPPPSX₄₀R₂₀ (SEQ ID NO: 5), wherein

X₁₀ is Trp, dTrp or Val;

X₁₁ is Trp, dTrp or Ser;

X₁₅ is Glu or dGlu

X₁₆ is Trp, dTrp, dGlu or Glu;

X₂₃ is Ile or dIle;

X₄₀ is an acylated amino acid, and R₂₀ is COOH or CONH₂, optionally wherein the peptide comprises one or more substitutions of Aib at any of positions 16, 18, 19, 24, 26 or 28, relative to the native Exendin4 sequence (SEQ ID NO: 1), or optionally an N-terminal extension of the peptide of SEQ ID NO: 5 by X₇X₈, wherein X₇ is an acylated amino acid (e.g., Lys) and X₈ is Gly or C₁-C₃ N-alkyl Gly, with position numbering relative to the native Exendin4 sequence (SEQ ID NO: 1), optionally with the proviso that when one of X₁₀ or X₁₁ is Trp or dTrp, the other is not Trp or dTrp.

In accordance with one embodiment a GLP-1 receptor antagonist peptide is provided having the amino acid sequence of


DVWRYLX₁₅EQAVREFIEWLVRGGPSSGAPPPSX₄₀R₂₀ (SEQ ID NO: 96), wherein

X₁₅ is dGlu;

X₄₀ is an acylated Lys and R₂₀ is COOH or CONH₂, wherein the acyl group of the acylated Lys is a C16-C18 acid or diacid, optionally linked via a spacer to the Lys side chain. In one embodiment the spacer comprises a minipep or a gamma glutamic acid subunit or any multiple or combination of such minipep or gamma Glu molecules. In one embodiment the peptide of SEQ ID NO: 96 is modified with 1, 2 or 3 amino acid substitutions, including for example, substitution with amino isobutyric acid (Aib) at one or more of positions 16, 18, 19, 24, 26 or 28, relative to the native Exendin4 sequence of SEQ ID NO: 1; or by the addition of a dipeptide X₇X₈ to the N-terminus of SEQ ID NO: 96, wherein X₇ is an acylated amino acid (e.g., Lys) and X₈ is Gly or C₁-C₃ N-alkyl Gly, with position numbering relative to the native Exendin4 sequence (SEQ ID NO: 1).

In one embodiment 1 to 3 amino acids are added to the N-terminus of the peptide of SEQ ID NO: 5 or an analog thereof. In one embodiment one of the amino acids comprising the N-terminal extension is an acylated amino acid. In one embodiment the N-terminal extension is a dipeptide, X₇X₈, wherein X₇ is an acylated lysine, optionally wherein the lysine is in the D-conformation and X₈ is any amino acid. In one embodiment the N-terminal extension is a self-cleaving dipeptide linked to the N-terminal alpha amine of a 9-29 exendin4 analog (e.g., a peptide of SEQ ID NO: 5) to form a prodrug of any of the GLP-1 antagonist of the present disclosure. One advantage of using a prodrug derivative of a GLP-1 antagonist is that such an approach extends peptide's biological half-life based on a strategy of inhibiting recognition of the prodrug by the GLP-1 receptor. In one embodiment the prodrug derivative comprises a self-cleaving dipeptide (A-B) covalently linked to the GLP-1 antagonist wherein the dipeptide is cleaved under physiological conditions and in the absence of enzymatic activity to restore full activity to the GLP-1 antagonist. In one embodiment the GLP-1 antagonist is modified by the covalent linkage of one or more dipeptides (A-B) to an amine of GLP-1 antagonist, wherein A is an amino

acid or a hydroxy acid and B is an N-alkylated amino acid linked to the GLP-1 antagonist through an amide bond between a carboxyl moiety of B and an amine of the GLP-1 antagonist. In one embodiment, A-B comprises the structure:



5

linked to the GLP-1 antagonist through an amide bond between the carboxyl of A-B and an amine of the GLP-1 antagonist wherein

R₁, R₂, R₄ and R₈ are independently selected from the group consisting of H, C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, (C₁-C₁₈ alkyl)OH, (C₁-C₁₈ alkyl)SH, (C₂-C₃ alkyl)SCH₃, (C₁-C₄ alkyl)CONH₂, (C₁-C₄ alkyl)COOH, (C₁-C₄ alkyl)NH₂, (C₁-C₄ alkyl)NHC(NH₂⁺)NH₂, (C₀-C₄ alkyl)(C₃-C₆ cycloalkyl), (C₀-C₄ alkyl)(C₂-C₅ heterocyclic), (C₀-C₄ alkyl)(C₆-C₁₀ aryl)R₇, (C₁-C₄ alkyl)(C₃-C₉ heteroaryl), and C₁-C₁₂ alkyl(W₁)C₁-C₁₂ alkyl, wherein W₁ is a heteroatom selected from the group consisting of N, S and O;

R₃ is selected from the group consisting of C₁-C₁₈ alkyl, (C₁-C₁₈ alkyl)OH, (C₁-C₁₈ alkyl)NH₂, (C₁-C₁₈ alkyl)SH, (C₀-C₄ alkyl)(C₃-C₆)cycloalkyl, (C₀-C₄ alkyl)(C₂-C₅ heterocyclic), (C₀-C₄ alkyl)(C₆-C₁₀ aryl)R₇, and (C₁-C₄ alkyl)(C₃-C₉ heteroaryl) or R₄ and R₃ together with the atoms to which they are attached form a pyrrolidine ring;

R₅ is NHR₆ or OH;

R₆ is H, C₁-C₈ alkyl; and

R₇ is selected from the group consisting of H and OH, wherein the chemical cleavage half-life (t_{1/2}) of A-B from said GLP-1 antagonist is at least about 1 hour to about 1 week in PBS under physiological conditions. In one embodiment the dipeptide A-B is covalently linked to the N-terminal alpha amine of the GLP-1 antagonist amino acid sequence. In one embodiment wherein R₁ is H, C₁-C₄ alkyl, (C₁-C₄ alkyl)OH or (C₁-C₄ alkyl)NH₂; R₂ is H, R₃ is C₁-C₆ alkyl; R₄ is H, C₁-C₄ alkyl, or (CH₂)(C₆ aryl)R₇; R₅ is NH₂; R₇ is H or OH and R₈ is hydrogen.

The present disclosure moreover provides pharmaceutical compositions comprising any of the GLP-1 antagonist peptides and variant peptides described herein and a pharmaceutically acceptable carrier, diluent, or excipient. In one embodiment a method of treating a patient suffering from atypical hypoglycemia is provided wherein the method comprises the step of administering to a patient in need thereof a pharmaceutical composition comprising a GLP-1 antagonist peptide or variant peptides described herein in an amount effective to elevate blood glucose levels.

In accordance with one embodiment a method of treating atypical hypoglycemia is provided wherein the method comprises the steps of administering any of the GLP-1 receptor antagonist peptides disclosed herein in an amount therapeutically effective for increasing blood glucose levels. In one embodiment the GLP-1 receptor antagonist is acylated with a fatty acid or diacid group of sufficient size to bind serum albumin with high affinity. In one embodiment the method comprises administering an acylated GLP-1 receptor antagonist, wherein the GLP-1 antagonist is acylated with a fatty acid or diacid group of sufficient size to bind serum albumin with high affinity. In one embodiment the N-terminal alpha amine of the GLP-1 receptor antagonist is acylated, optionally with second acylation at the C-terminus. In one embodiment the GLP-1 receptor antagonist is acylated at the C- terminus, optionally wherein the acylated amino acid is the C-terminal amino acid, and optionally the GLP-1 antagonist is further modified by the linkage of a self- cleaving dipeptide via an amide bond, optionally wherein an amino acid of the dipeptide is acylated with a fatty-acyl group of sufficient size to bind serum albumin with high affinity. In one embodiment an acylated amino acid is added to the C- terminus of SEQ ID NO: 11 at position 40 and optionally the added acylated amino acid is Lys acylated with a C14-C20 fatty acid or fatty diacid, optionally linked to the amino acid side chain via any of the spacers disclosed herein.

In one embodiment the pharmaceutical compositions for treating atypical hypoglycemia comprise any of the GLP-1 receptor antagonists disclosed herein in combination with any existing therapeutics useful for treating hypoglycemia. For example, the pharmaceutical composition may include a GLP-1 receptor antagonist of the present invention and one or more of the following: glucose supplements (e.g., dextrose); glucose-elevating agents such as glucagon and glucagon analogs and inhibitors of insulin secretion (e.g., diazoxide, octreotide).

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph presenting the dose dependent change in blood glucose levels over time after subcutaneous administration of a vehicle control, Ex-4 (a GLP-1 agonist having an amino acid sequence of SEQ ID NO: 1), or a GLP-1 antagonist peptide (DVSRYLEEQAVREFIEWLVRGGPSSGAPPPSK₄₀[mPEG-γE-C16]acid; SEQ ID NO: 16 to mice followed by intraperitoneal administration of glucose (1.5 g glucose per kg body weight), wherein the glucose is administered subcutaneously 4hr after the GLP-1 antagonist.

Figs. 2A & 2B present data from a glucose tolerance test wherein mice are subcutaneously administered the GLP-1 antagonist followed four hours later by intraperitoneal administration of glucose (1.5 g glucose per kg body weight). The results

demonstrate that the GLP-1 antagonist of SEQ ID NO: 16 (Fig. 2A) is a full antagonist and has a much higher potency than the GLP-1 antagonist Ex-9-40 (DVSKQMEEEAVRLFIEWLKNNGPSSGAPPPS; SEQ ID NO: 2); Fig. 2B).

Fig. 3 presents data from a glucose tolerance test investigating the effect of Aib substitutions on the efficacy of the GLP-1 antagonists. Mice are subcutaneously administered the GLP-1 antagonist followed four hours later by intraperitoneal administration of glucose (1.5 g glucose per kg body weight). Fig. 3 demonstrates the activity of a GLP-1 antagonist peptide analog of 9-40Jant4-K₄₀ (DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK; SEQ ID NO: 3) that comprises the sequence of (SEQ ID NO: 47), and derivatives thereof comprising a series of Aib substitutions s SEQ ID NO: 43 (Aib at position 20), SEQ ID NO: 44 (Aib at position 18), and, SEQ ID NO: 45 (Aib at position 11), SEQ ID NO: 46 (Aib at position 10).

Fig. 4 presents data from a glucose tolerance test investigating the effect of D-amino acid substitutions on the efficacy of the GLP-1 antagonists. Mice are subcutaneously administered the GLP-1 antagonist followed four hours later by intraperitoneal administration of glucose (1.5 g glucose per kg body weight). The GLP-1 antagonist activity of an (miniPEG)₂-γE-C16 acylated 9-40Jant4-K₄₀ (DVSSYLEEQAVREFIAWLKGGPSSGAPPPSX₄₀ (SEQ ID NO: 12)) peptide SEQ ID NO: 48 wherein X₄₀ is Lys acylated with (miniPEG)₂-gamma Glu-C16 and has a C-terminal amide) relative to vehicle control and variants comprising a substitution wherein X₄₀ is Lys acylated with C16 and a C-terminal amide with the corresponding amino acid in the D-configuration as follows: SEQ ID NO: 49 (*d-Glu*¹⁵), SEQ ID NO: 50 (*d-Val*¹⁹), SEQ ID NO: 51 (*d-Ile*²³).

Figs. 5A-5D provide data on prodrug derivatives of GLP-1 receptor antagonists of the present invention. Fig. 5A presents mass spectrophotometer data for the prodrug dK⁷(mPeg-γE-diacid C18) **N-Me-Gly**⁸ peptide SEQ ID NO: 19 incubated in PBS at 37 °C over time. Figs. 5B-5D are graphs presenting the GLP-1 antagonist activity of a dipeptide prodrug of DVSRYLEEQAVREFIEWLVRGGPSSGAPPPSX₄₀; SEQ ID NO: 18, wherein the peptide has been modified with a covalently linked dK⁷(mPeg-γE-diacid C18) **N-iPr-Gly**⁸ dipeptide, in a glucose tolerance test, wherein a glucose challenge is administered 24h (Fig. 5B), 48h (Fig. 5C) or 120h (Fig. 5D) after administration of the antagonist.

Figs. 6A & 6B provide data on derivatives of GLP-1 receptor antagonists of the present invention comprising two acylated amino acids. Figs. 6A and 6B are graphs presenting the results of a glucose tolerance test, wherein a glucose challenge is administered 24h (Fig. 6A) or 48h (Fig. 6B) after administration of the antagonist, wherein

SEQ ID NO: 16 is R¹², E²⁴, R²⁸, K⁴⁰[mPEG-γE-C16]-(Jant4, 9-40)acid (SEQ ID NO: 16);

SEQ ID NO: 17 is dK⁷(mPeg-γE(C18-diacid)G⁸, R¹², E²⁴, R²⁸, K⁴⁰[mPEG-γE-C16]-(Jant4, 9-40)acid (SEQ ID NO: 17);

SEQ ID NO: 18 dK⁷(mPeg-γE(C18-diacid) **i-Pr**, G⁸, R¹², E²⁴, R²⁸, K⁴⁰[mPEG-γE-C16]-(Jant4, 9-40)acid (SEQ ID NO: 18);

SEQ ID NO: 19 dK⁷(mPeg-γE(C18-diacid) **N-Me**, G⁸, R¹², E²⁴, R²⁸, K⁴⁰[mPEG-γE-C16]-(Jant4, 9-40)acid (SEQ ID NO: 19);

SEQ ID NO: 20 dK⁷(K(mPeg-γE-C18 diacid)₂ G⁸, R¹², E²⁴, R²⁸ K⁴⁰[mPEG-γE-C18 diacid] (Jant4, 9-40)amide (SEQ ID NO: 20);

SEQ ID NO: 21 dK⁷(K(mPeg-γE-C18 diacid)₂ G⁸, R¹², E²⁴, R²⁸ K⁴⁰[mPEG-γE-C16] (Jant4, 9-40)amide (SEQ ID NO: 21);

SEQ ID NO: 22 dK⁷(K(mPeg-γE-C18 diacid)₂ **N-Me**, G⁸, R¹², E²⁴, R²⁸ K⁴⁰[mPEG-γE-C16] (Jant4, 9-40)amide (SEQ ID NO: 22).

Fig. 7 provides a table of various N-terminal acylated GLP-1 antagonists (MBX 1391; SEQ ID NO: 118; MBX 1401; SEQ ID NO: 119; MBX 1402; SEQ ID NO: 120; MBX 1403; SEQ ID NO: 121; MBX 1404; SEQ ID NO: 122; MBX 1406; SEQ ID NO: 123; MBX 1407; SEQ ID NO: 124; MBX 1408; SEQ ID NO: 125; MBX 1416; SEQ ID NO: 126) prepared in accordance with the present disclosure. All of these GLP-1 analogs are also acylated at the carboxy terminus with the exception of the final compound, MBX 1416 with is only acylated at the N-terminus.

Fig. 8 is a graph presenting glucose blood levels in mice subcutaneously injected with a double acylated GLP-1 antagonist (MBX 1407; SEQ ID NO: 116)) at three different dosages 10 nmol/kg, 30 nmol/kg, 100 nmol/kg and 300 nmol/kg, as measured at 24 hrs, 48 hrs, and 72 hrs demonstrating a dose dependent response.

Fig. 9 is a graph presenting glucose blood levels in mice subcutaneously injected with a 300 nmol/kg of a double acylated GLP-1 antagonist (MBX 1407; **X-DVSSYLEEQAVREFIAWLVRGGPSSGAPPPSO-acid**; SEQ ID NO: 116) vs a single acylated GLP-1 antagonist (MBX 1342; **DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSO-amide**; SEQ ID NO: 117) over time, where X=C18-diacid and O=Lys(C18-diacid). The single site lipidated GLP-1 antagonist is more potent than the double site lipidated GLP-1 antagonist.

Fig. 10 presents the IC₅₀ (nMoles) of various GLP-1 antagonist analogs (MBX 1342; SEQ ID NO: 127; MBX 1373; SEQ ID NO: 128; MBX 1416; SEQ ID NO: 126; MBX 1417; SEQ ID NO: 129; MBX 1418; SEQ ID NO: 130) as measured in an *in vitro* assay using GLP-1R over-expressing 293 cells.

Fig. 11A & 11B are graphs presenting the change in body weight in mice subcutaneously injected with a 300 nmol/kg of a double acylated GLP-1 antagonist (MBX 1407; Fig. 11A) vs a single acylated GLP-1 antagonist (MBX 1342; Fig. 11B) over time. The single site lipidated GLP-1 antagonist is more potent than the double site lipidated GLP-1 antagonist.

Fig. 12 presents data on the change in blood glucose of mice subcutaneously injected with a 100 or 300 nmol/kg of a nonacylated GLP-1 antagonist (MBX 1118 (Ex-9)), a double acylated GLP-1 antagonist (MBX 1407) and a single acylated GLP-1 antagonist (MBX 1416) over time, as measured at days 2, 4, 7, 9, 11 and 14.

Fig. 13 shows the results of a glucose tolerance test conducted at day 14 after subcutaneously injection of a 100 or 300 nmol/kg of a nonacylated GLP-1 antagonist (MBX 1118 (Ex-9)), a double acylated GLP-1 antagonist (MBX 1407) and a single acylated GLP-1 antagonist (MBX 1416).

DETAILED DESCRIPTION

DEFINITIONS

In describing and claiming the invention, the following terminology will be used in accordance with the definitions set forth below.

The term “about” as used herein means greater or lesser than the value or range of values stated by 10 percent but is not intended to designate any value or range of values to only this broader definition. Each value or range of values preceded by the term “about” is also intended to encompass the embodiment of the stated absolute value or range of values.

As used herein the term “amino acid” encompasses any molecule containing both amino and carboxyl functional groups, wherein the amino and carboxylate groups are attached to the same carbon (the alpha carbon). The alpha carbon optionally may have one or two further organic substituents. An amino acid can be designated by its three-letter code, one letter code, or in some cases by the name of its side chain. For example, a non-canonical amino acid comprising a cyclohexane group attached to the alpha carbon is termed “cyclohexane” or “cyclohexyl.” For the purposes of the present disclosure designation of an amino acid without specifying its stereochemistry is intended to encompass either the L or D form of the amino acid, or a racemic mixture. However, in the instance where an amino acid is designated by its three letter code (i.e., Lys), such a designation is intended to specify the native L form of the amino acid, whereas the D form will be specified by inclusion of a lower case d before the three letter code or single code (i.e., dLys or dK).

As used herein the term “hydroxyl acid” refers to amino acids that have been

modified to replace the alpha carbon amino group with a hydroxyl group.

As used herein the term “non-coded amino acid” encompasses any amino acid that is not an L-isomer of any of the following 20 amino acids: Ala, Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, Tyr.

5 A “bioactive polypeptide” refers to polypeptides which can exert a biological effect *in vitro* and/or *in vivo*.

As used herein a general reference to a peptide is intended to encompass peptides that have modified amino and carboxy termini. For example, an amino acid sequence designating the standard amino acids is intended to encompass standard amino acids at the
10 N- and C- terminus as well as a corresponding hydroxyl acid at the N-terminus and/or a corresponding C-terminal amino acid modified to comprise an amide group in place of the terminal carboxylic acid.

As used herein an “acylated” amino acid is an amino acid comprising an acyl group which is non-native to a naturally occurring amino acid, regardless by the means by which it is produced. Exemplary methods of producing acylated amino acids and acylated
15 peptides are known in the art and include acylating an amino acid before inclusion in the peptide or peptide synthesis followed by chemical acylation of the peptide. In some embodiments, the acyl group causes the peptide to have one or more of (i) a prolonged half-life in circulation, (ii) a delayed onset of action, (iii) an extended duration of action,
20 (iv) an improved resistance to proteases, and (v) increased potency at the GLP-1 receptor.

As used herein, an “alkylated” amino acid is an amino acid comprising an alkyl group which is non-native to a naturally occurring amino acid, regardless of the means by which it is produced. Exemplary methods of producing alkylated amino acids and
25 alkylated peptides are known in the art and including alkylating an amino acid before inclusion in the peptide or peptide synthesis followed by chemical alkylation of the peptide. Without being held to any particular theory, it is believed that alkylation of peptides will achieve similar, if not the same, effects as acylation of the peptides, e.g., a prolonged half-life in circulation, a delayed onset of action, an extended duration of action, an improved resistance to proteases.

30 As used herein, the term “pharmaceutically acceptable carrier” includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents. The term also encompasses any of the agents approved by a regulatory agency of the US Federal government or listed in the US Pharmacopeia for use in animals, including
35 humans.

As used herein the term “pharmaceutically acceptable salt” refers to salts of compounds that retain the biological activity of the parent compound, and which are not biologically or otherwise undesirable. Many of the compounds disclosed herein are

capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.

As used herein, the term “hydrophilic moiety” refers to any compound that is readily water-soluble or readily absorbs water, and which are tolerated *in vivo* by mammalian species without toxic effects (i.e. are biocompatible). Examples of hydrophilic moieties include polyethylene glycol (PEG), polylactic acid, polyglycolic acid, a poly(lactic-co-glycolic) acid copolymer, polyvinyl alcohol, polyvinylpyrrolidone, polymethoxazoline, polyethyloxazoline, polyhydroxyethyl methacrylate, polyhydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, and derivatized celluloses such as hydroxymethylcellulose or hydroxyethylcellulose and copolymers thereof, as well as natural polymers including, for example, albumin, heparin and dextran.

As used herein, the term “treating” includes alleviation of the symptoms associated with a specific disorder or condition and/or preventing or eliminating said symptoms. For example, as used herein the term “treating hypoglycemia” will refer in general to maintain or increase blood glucose levels to near normal levels.

As used herein an “effective” amount or a “therapeutically effective amount” of a GLP-1 receptor antagonist refers to a nontoxic but sufficient amount of a GLP-1 antagonist to provide the desired effect. For example, one desired effect would be the prevention or treatment of hypoglycemia. The amount that is “effective” will vary from subject to subject, depending on the age and general condition of the individual, mode of administration, and the like. Thus, it is not always possible to specify an exact “effective amount.” However, an appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.

The term, “parenteral” means not through the alimentary canal but by some other route such as intranasal, inhalation, subcutaneous, intramuscular, intraspinal, or intravenous.

As used herein the term “derivative” is intended to encompass chemical modification to a compound (e.g., an amino acid), including chemical modification *in vitro*, e.g. by introducing a group in a side chain in one or more positions of a polypeptide, e.g. a nitro group in a tyrosine residue, or iodine in a tyrosine residue, or by conversion of a free carboxylic group to an ester group or to an amide group, or by converting an amino group to an amide by acylation, or by acylating a hydroxy group rendering an ester, or by alkylation of a primary amine rendering a secondary amine or linkage of a hydrophilic moiety to an amino acid side chain. Other derivatives are obtained by oxidation or reduction of the side-chains of the amino acid residues in the polypeptide.

The term “identity” as used herein relates to the similarity between two or more sequences. Identity is measured by dividing the number of identical residues by the total

number of residues and multiplying the product by 100 to achieve a percentage. Thus, two copies of exactly the same sequence have 100% identity, whereas two sequences that have amino acid deletions, additions, or substitutions relative to one another have a lower degree of identity. Those skilled in the art will recognize that several computer programs, such as those that employ algorithms such as BLAST (Basic Local Alignment Search Tool, Altschul et al. (1993) J. Mol. Biol. 215:403-410) are available for determining sequence identity.

As used herein, the term “selectivity” of a molecule for a first receptor relative to a second receptor refers to the following ratio: EC_{50} of the molecule at the second receptor divided by the EC_{50} of the molecule at the first receptor. For example, a molecule that has an EC_{50} of 1 nM at a first receptor and an EC_{50} of 100 nM at a second receptor has 100-fold selectivity for the first receptor relative to the second receptor.

As used herein an amino acid “modification” refers to a substitution of an amino acid, or the derivation of an amino acid by the addition and/or removal of chemical groups to/from the amino acid, and includes substitution with any of the 20 amino acids commonly found in human proteins, as well as atypical or non-naturally occurring amino acids. Commercial sources of atypical amino acids include Sigma- Aldrich (Milwaukee, WI), ChemPep Inc. (Miami, FL), and Genzyme Pharmaceuticals (Cambridge, MA). Atypical amino acids may be purchased from commercial suppliers, synthesized de novo, or chemically modified or derivatized from naturally occurring amino acids.

As used herein an amino acid “substitution” refers to the replacement of one amino acid residue by a different amino acid residue.

As used herein, the term “conservative amino acid substitution” is defined herein as exchanges within one of the following five groups:

- I. Small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, Gly;
- II. Polar, negatively charged residues and their amides:
Asp, Asn, Glu, Gln, cysteic acid and homocysteic acid;
- III. Polar, positively charged residues:
His, Arg, Lys; Ornithine (Orn)
- IV. Large, aliphatic, nonpolar residues:
Met, Leu, Ile, Val, Cys, Norleucine (Nle), homocysteine
- V. Large, aromatic residues:
Phe, Tyr, Trp, acetyl phenylalanine


Throughout the application, all references to a particular amino acid position by number (e.g., position 28) refer to the amino acid at that position in native Exendin4 (SEQ ID NO: 1) or the corresponding amino acid position in any analogs thereof. For example,

a reference herein to “position 28” would mean the corresponding position 27 for an analog of Exendin4 in which the first amino acid of SEQ ID NO: 1 has been deleted. Accordingly 9-39 Exendin4 represents a N- terminally truncated Exendin4 peptide wherein the first 8 amino acids have been deleted. In addition a reference to a position greater than 39 (native Exendin4 only has 39 amino acids) is intended to refer to amino acid position in an analog having a C-terminus amino acid extension after the corresponding position 39 of SEQ ID NO: 1.

As used herein the general term “polyethylene glycol chain” or “PEG chain”, refers to mixtures of condensation polymers of ethylene oxide and water, in a branched or straight chain, represented by the general formula $H(OCH_2CH_2)_nOH$, wherein n is at least 2. “Polyethylene glycol chain” or “PEG chain” is used in combination with a numeric suffix to indicate the approximate average molecular weight thereof. For example, PEG-5,000 refers to polyethylene glycol chain having a total molecular weight average of about 5,000 Daltons.

As used herein the term “pegylated” and like terms refers to a compound that has been modified from its native state by linking a polyethylene glycol chain to the compound. A “pegylated polypeptide” is a polypeptide that has a PEG chain covalently bound to the polypeptide.

As used herein the term “miniPEG” or “OEG” defines a functionalized polyethylene compound comprising the structure:



As used herein a “linker” or “spacer” is a bond, molecule or group of molecules that binds two separate entities to one another. Linkers may provide for optimal spacing of the two entities or may further supply a labile linkage that allows the two entities to be separated from each other. Labile linkages include photocleavable groups, acid-labile moieties, base-labile moieties, and enzyme- cleavable groups.

As used herein a “dimer” is a complex comprising two subunits covalently bound to one another via a linker. The term dimer, when used absent any qualifying language, encompasses both homodimers and heterodimers. A homodimer comprises two identical subunits, whereas a heterodimer comprises two subunits that differ, although the two subunits are substantially similar with one another.

As used herein the term C16-C20 fatty acid designates the structure: $CO(CH_2)_{14-20}CH_3$ and the term C16-C20 diacid designates the structure: $-CO(CH_2)_{14-20}COOH$, wherein the prefix “C16-C20” designates the variable total number of carbons in the compounds encompassed by the designation. For example, a C18 diacid represents the

structure: $-\text{CO}(\text{CH}_2)_{16}\text{COOH}$. As used herein a generic reference to an acylated amino acid encompasses both an amino acid having its side chain acylated with a fatty acid and an amino acid having its side chain acylated with a diacid.

Physiological conditions as disclosed herein are intended to include a temperature of about 35 to 40 °C and a pH of about 7.0 to about 7.4, and more typically include a pH of 7.2 to 7.4 and a temperature of 36 to 38 °C. Since physiological pH and temperature are tightly regulated in humans within a highly defined range, the speed of conversion from dipeptide/drug complex (prodrug) to drug will exhibit high intra and interpatient reproducibility.

The term “C₁-C_n alkyl” wherein n can be from 1 through 6, as used herein, represents a branched or linear alkyl group having from one to the specified number of carbon atoms. Typical C₁-C₆ alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-Butyl, sec-butyl, tert-butyl, pentyl, hexyl and the like.

The terms “C₂-C_n alkenyl” wherein n can be from 2 through 6, as used herein, represents an olefinically unsaturated branched or linear group having from 2 to the specified number of carbon atoms and at least one double bond. Examples of such groups include, but are not limited to, 1-propenyl, 2-propenyl ($-\text{CH}_2-\text{CH}=\text{CH}_2$), 1,3-butadienyl, ($-\text{CH}=\text{CHCH}=\text{CH}_2$), 1-butenyl ($-\text{CH}=\text{CHCH}_2\text{CH}_3$), hexenyl, pentenyl, and the like.

The term “C₂-C_n alkynyl” wherein n can be from 2 to 6, refers to an unsaturated branched or linear group having from 2 to n carbon atoms and at least one triple bond. Examples of such groups include, but are not limited to, 1-propynyl, 2-propynyl, 1-butylnyl, 2-butylnyl, 1-pentylnyl, and the like.

As used herein the term “aryl” refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl, and the like. The size of the aryl ring and the presence of substituents or linking groups are indicated by designating the number of carbons present. For example, the term “(C₁-C₃ alkyl)(C₆-C₁₀ aryl)” refers to a 5 to 10 membered aryl that is attached to a parent moiety via a one to three membered alkyl chain.

The term “heteroaryl” as used herein refers to a mono- or bi-cyclic ring system containing one or two aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring. The size of the heteroaryl ring and the presence of substituents or linking groups are indicated by designating the number of carbons present. For example, the term “(C₁-C_n alkyl)(C₅-C₆ heteroaryl)” refers to a 5 or 6 membered heteroaryl that is attached to a parent moiety via a one to “n” membered alkyl chain.

As used herein, the term “halo” refers to one or more members of the group consisting of fluorine, chlorine, bromine, and iodine.

As used herein the term “patient” without further designation is intended to

encompass any warm blooded vertebrate domesticated animal (including for example, but not limited to livestock, horses, cats, dogs and other pets) and humans and is not limited to individuals under the direct care of a physician.

5 The term “isolated” as used herein means having been removed from its natural environment.

The term “purified,” as used herein relates to the isolation of a molecule or compound in a form that is substantially free of contaminants normally associated with the molecule or compound in a native or natural environment and means having been increased in purity as a result of being separated from other components of the original composition. The term “purified peptide” is used herein to describe a peptide which has
10 been separated from other compounds including, but not limited to nucleic acid molecules, lipids and carbohydrates.

As used herein, the term “peptide” encompasses a sequence of 2 or more amino acids and typically less than 50 amino acids, wherein the amino acids are naturally occurring or coded or non-naturally occurring or non-coded amino acids. Non-naturally occurring amino acids refer to amino acids that do not naturally occur *in vivo* but which, nevertheless, can be incorporated into the peptide structures described herein. “Non-coded” as used herein refer to an amino acid that is not an L- isomer of any of the following 20 amino acids: Ala, Cys, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro,
15 Gln, Arg, Ser, Thr, Val, Trp, Tyr.

As used herein, “partly non-peptidic” refers to a molecule wherein a portion of the molecule is a chemical compound or substituent that has biological activity and that does not comprise a sequence of amino acids.

A “peptidomimetic” refers to a chemical compound having a structure that is different from the general structure of an existing peptide, but that functions in a manner similar to the existing peptide, e.g., by mimicking the biological activity of that peptide. Peptidomimetics typically comprise naturally occurring amino acids and/or unnatural amino acids, but can also comprise modifications to the peptide backbone. For example, a peptidomimetic may include a sequence of naturally- occurring amino acids with the
25 insertion or substitution of a non-peptide moiety, e.g. a retroinverso fragment, or incorporation of non-peptide bonds such as an azapeptide bond (CO substituted by NH) or pseudo-peptide bond (e.g. NH substituted with CH₂), or an ester bond (e.g., depsipeptides, wherein one or more of the amide (-CONHR-) bonds are replaced by ester (COOR) bonds). Alternatively the peptidomimetic may be devoid of any naturally-occurring amino
30 acids.

As used herein the term “charged amino acid” or “charged residue” refers to an amino acid that comprises a side chain that is negatively charged (i.e., de- protonated) or

positively charged (i.e., protonated) in aqueous solution at physiological pH. For example, negatively charged amino acids include aspartic acid, glutamic acid, cysteic acid, homocysteic acid, and homoglutamic acid, whereas positively charged amino acids include arginine, lysine and histidine. Charged amino acids include the charged amino acids among the 20 amino acids commonly found in human proteins, as well as atypical or non-naturally occurring amino acids.

As used herein the term “acidic amino acid” refers to an amino acid that comprises a second acidic moiety (other than the alpha carboxylic acid of the amino acid), including for example, a side chain carboxylic acid or sulfonic acid group.

As used herein, the term “prodrug” is defined as any compound that undergoes chemical modification before exhibiting its full pharmacological effects.

As used herein, a “dipeptide” is the result of the linkage of an α -amino acid or α -hydroxyl acid to another amino acid, through a peptide bond.

As used herein the term “chemical cleavage” absent any further designation encompasses a non-enzymatic reaction that results in the breakage of a covalent chemical bond.

As used herein the term “atypical hypoglycemia” defines a condition of hypoglycemia occurring in a patient independent of exogenous insulin administration.

ABBREVIATIONS:

Lower case k = D-isomer of lysine

Upper case K = L-isomer of lysine

γ E = L-isomer of gamma, glutamic acid

(miniPEG)₂ = COCH₂OCH₂CH₂OCH₂CH₂NH

COC₁₆H₃₂CO₂H = (C18 diacid)

(N-Me)G = sarcosine

EMBODIMENTS

In accordance with one embodiment of the present disclosure, compositions and methods are provided for treating patients suffering from a hypoglycemic condition that results independently of exogenous insulin administration (i.e., atypical hypoglycemia). In accordance with the present disclosure a composition comprising a GLP-1 antagonist is administered to a patient suffering from atypical hypoglycemia in an amount sufficient to increase blood glucose levels and/or alleviate associated acute symptoms and chronic outcomes associated with hypoglycemia. In one embodiment the patient experiencing atypical hypoglycemia also has a condition of hyperinsulinemia. In one embodiment the hyperinsulinemic condition occurs after the patient has received bariatric surgery.

In accordance with one embodiment a method of treating patients suffering from atypical hypoglycemia comprises the administering an acylated GLP-1 receptor antagonist peptide, wherein the GLP-1 receptor antagonist peptide is acylated at the N-terminus and/or C-terminus with a fatty acid or fatty diacid group of sufficient size to bind serum albumin with high affinity. In one embodiment a C14-C20 acyl group is covalently linked to the N-terminal alpha amine of the GLP-1 receptor antagonist peptide.

In one embodiment a GLP-1 receptor antagonist is acylated at the N-terminus of the GLP-1 receptor antagonist, optionally wherein an acetyl group is covalently linked to the N-terminal alpha amine of the glucagon peptide. The acyl group of the acylated glucagon peptide can be of any size, e.g., any length carbon chain, and can be linear or branched. In some specific embodiments of the invention, the acyl group is a C12 to C30 fatty acid or fatty diacid. For example, the acyl group can be any of a C12 fatty acid/diacid, C14 fatty acid/diacid, C16 fatty acid/diacid, C18 fatty acid/diacid, C20 fatty acid/diacid, C22 fatty acid/diacid, C24 fatty acid/diacid, C26 fatty acid/diacid, C28 fatty acid/diacid, or a C30 fatty acid/diacid. In some embodiments, the acyl group is a C14 to C20 fatty acid, e.g., a C14 fatty acid or fatty diacid, a C16 fatty acid or fatty diacid, or a C16 fatty acid or fatty diacid.

In accordance with one embodiment the acylated GLP-1 receptor antagonist peptide comprises an amino acid sequence of DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK (SEQ ID NO: 3) or an analog thereof having at least 95% sequence identity with SEQ ID NO: 3 while retaining GLP-1 receptor antagonist activity.

In accordance with one embodiment the acylated GLP-1 receptor antagonist peptide of the present disclosure comprises an analog of the peptide DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK (SEQ ID NO: 3), wherein the GLP-1 receptor antagonist differs from SEQ ID NO: 3 by 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications, wherein the modifications are selected from amino acid substitutions, additions or modifications to the amino acid structure, including but not limited to acylation and/or amidation of the C terminal amino acid. In one embodiment the amino acid modification are amino acid substitutions at one or more of positions 12, 16, 18, 19, 24, 26, 27 and 28 of the peptide and/or substitution with the d-isomer at one or more of positions 15, 16, 17, 19, 20, 21 and 23 (numbering relative to native Exendin4 (SEQ ID NO: 1). In one embodiment the analog of SEQ ID NO: 3 is further modified by the acylation of the C-terminal amino acid side chain with a C16-C18 fatty acid or diacid, optionally via a spacer.

In accordance with one embodiment a GLP-1 receptor antagonist is provided comprising the amino acid sequence of DVSRYLEEQAVREFIEWLVRGGPSSGAPPPSK (SEQ ID NO: 4), or an amino acid

sequence that differs from SEQ ID NO: 4 by 1, 2, 3, 4 or 5 amino acid substitutions while retaining GLP-1 receptor antagonist activity, with the proviso that the GLP-1 antagonist peptide does not comprise the sequence of SEQ ID NO: 3. In one embodiment a peptide is provided that differs from the peptide of SEQ ID NO: 4 by one or more of the following:

- i. substitution of 1, 2 or 3 amino acids at any of positions 7, 10, 11, 13 or 16 with Trp or dTrp;
- i. substitution of 1, 2 or 3 amino acids at any of positions 15, 16 or 23 with the corresponding amino acid in the D conformation;
- ii. substitution of 1, 2 or 3 amino acids at any of positions 16, 18, 19, 24, 26, or 28 with Aib;
- iii. substitution at position 12 with an acylated amino acid, optionally an acylated lysine;
- iv. substitution at position 16 with dGlu, Asp, homoglutamic acid or homocysteic acid;
- v. substitution at position 19 with cyclopropane, cyclopentane, cyclohexane or phenyl glycine;
- vi. substitution at position 20 with dArg, homolysine or citrulline;
- vii. substitution of the native C-terminal carboxyl group with an amide;
- viii. addition of a N-terminal extension of 1 to 3 amino acids, optionally wherein one of the N-terminal extension amino acids is acylated;
- ix. substitution of the C-terminal amino acid with an acylated amino acid;
- x. any combination of i) through x).

In accordance with one embodiment a GLP-1 receptor antagonist is provided comprising the amino acid sequence of R₁₀-DVX₁₁X₁₂YLX₁₅X₁₆QAX₁₉X₂₀EFX₂₃EWLVRRGGPSSGAPPPSX₄₀-R₂₀ SEQ ID NO: 23), wherein

R₁₀ is NH₂, -CO(CH₂)₁₄₋₂₀CH₃, -CO(CH₂)₁₄₋₂₀COOH or an N-terminal extension of 1, 2 or 3 amino acids, wherein one of the amino acids of the N-terminal extension is acylated with a C16-C18 fatty acid or diacid, optionally via a spacer, optionally wherein R₁₀ is a dipeptide of the structure: X₇X₈, wherein X₇ is an acylated amino acid, optionally acylated Lys or acylated dLys, and X₈ is Gly or a C₁-C₄ N-alkylated Gly;

X₁₁ is Trp, dTrp or Ser;

X₁₂ is Arg or an acylated amino acid, optionally acylated Lys;

X₁₅ is Glu or dGlu;

X₁₆ is Glu, dGlu, Asp, homoglutamic acid or homocysteic acid;

X₁₉ is Val, cyclopropane, cyclopentane, cyclohexane or phenyl glycine;

X₂₀ is Arg, homolysine or citrulline;

X₂₃ is Ile, or dIle;

5 X₄₀ is an acylated amino acid, optionally an acylated Lys; and

10 R₂₀ is COOH or CONH₂, optionally wherein 1, 2 or 3 amino acids selected from positions 7, 10, 13, or 16 are substituted with Trp or dTrp, with an optional proviso that positions 10 and 11 are not both Trp or dTrp; with a further optional proviso that that R₁₀ and X₁₂ cannot both comprise an acylated amino acid; optionally wherein 1, 2 or 3 amino acids at any of positions 16, 18, 19, 24, 26, or 28 are substituted with Aib.

15 In one embodiment only one of positions 7, 12 and 40 of the peptide of SEQ ID NO: 23 comprises an acylated amino acid. In one embodiment two of positions 7, 12 and 40 of the peptide of SEQ ID NO: 23 comprises an acylated amino acid. In one embodiment the acylated amino acids at position 7, 12 and 40 are independently an amino acid comprising a structure of Formula I (optionally, Lys), or Formula II (optionally, Ser), wherein each of Formula I, and II is:



Wherein n= 1 to 4

[Formula I] and



wherein n + 1 to 4

[Formula II]

30 In one embodiment a peptide of SEQ ID NO: 23 is provided wherein R₁₀ is X₇X₈, wherein X₇ is an acylated Lys or acylated dLys, X₁₂ is Arg and X₄₀ is an acylated Lys. In one embodiment a peptide of SEQ ID NO: 23 is provided wherein R₁₀ is NH₂, X₁₂ is an acylated Lys and X₄₀ is an acylated Lys. In one embodiment a peptide of SEQ ID NO: 23 is provided wherein R₁₀ is NH₂, X₁₂ is Arg and X₄₀ is an acylated Lys. In one embodiment

the acylated amino acids of the peptide of SEQ ID NO: 23 are acylated Lys residues, optionally wherein the acylated Lys residues are independently acylated with a C14-C24 fatty acid or fatty diacid, or a C16-C18 fatty acid or fatty diacid, optionally wherein the fatty acid or fatty diacid is linked to the side chain of the Lys residue via any of the spacer molecules disclosed herein.

In accordance with one embodiment a GLP-1 receptor antagonist is provided comprising the amino acid sequence of R₁₀-DVX₁₁X₁₂YLEX₁₆QAVREFIEWLVRGGPSSGAPPPSX₄₀-R₂₀ SEQ ID NO: 24), wherein

R₁₀ is NH₂-CO(CH₂)₁₄₋₂₀CH₃, -CO(CH₂)₁₄₋₂₀COOH or a dipeptide of the structure: X₇X₈, wherein X₇ is an acylated amino acid, optionally acylated Lys or acylated dLys, and X₈ is Gly or a C1-C4 N-alkylated Gly;

X₁₁ is Trp, dTrp or Ser;

X₁₂ is Arg or an acylated amino acid, optionally acylated Lys;

X₁₆ is Glu or Asp;

X₄₀ is an acylated amino acid, optionally an acylated Lys; and

R₂₀ is COOH or CONH₂, optionally wherein 1, 2 or 3 amino acids selected from positions 16, 17, 18, 20 or 21 are substituted with the corresponding amino acid in the D conformation, and/or 1, 2 or 3 amino acids at any of positions 16, 18, 19, 24, 26, or 28 are substituted with Aib.

In accordance with one embodiment a GLP-1 receptor antagonist is provided comprising the amino acid sequence of R₁₀-DVX₁₁X₁₂YLEX₁₆QAVREFIEWLVRGGPSSGAPPPSX₄₀-R₂₀ SEQ ID NO: 24), wherein

R₁₀ is a dipeptide of the structure: X₇X₈, wherein X₇ is an acylated Lys or acylated dLys, and X₈ is Gly or Sarcosine;

X₁₁ is Trp or dTrp;

X₁₂ is Arg;

X₁₆ is Glu;

X₄₀ is an acylated Lys; and

R₂₀ is COOH or CONH₂, wherein said acylated Lys residues of the peptide are independently acylated with a C16-C18 fatty acid or fatty diacid optionally via a spacer as disclosed herein, optionally wherein 1, 2 or 3 amino acids at any of positions 16, 18, 19, 24, 26, or 28 are substituted with Aib.

In one embodiment a GLP-1 receptor antagonist is provided, wherein the antagonist comprises the amino acid sequence of

DX₁₀X₁₁X₁₂YLX₁₅X₁₆QAVREFX₂₃X₂₄WLVRRGGPSSGAPPPS (SEQ ID NO:

98);

wherein

X₁₀ is Trp, dTrp or Val;

X₁₁ is Trp, dTrp or Ser;

5 X₁₂ is Arg, Lys or Ser

X₁₅ is Glu or dGlu

X₁₆ is Trp, dTrp, dGlu or Glu;

X₂₃ is Ile or dIle;

X₂₄ is Ala or Glu;

10 and

said GLP-1 receptor antagonist is acylated with a fatty acid or diacid group of sufficient size to bind serum albumin with high affinity, optionally wherein an amino acid of the GLP-1 receptor antagonist is acylated with a C16-C18 fatty acid or C16- C18 fatty diacid.

15 In one embodiment a GLP-1 receptor antagonist is provided, wherein the antagonist comprises the amino acid sequence of

R₁₀-DX₁₀X₁₁X₁₂YLX₁₅X₁₆QAVREFX₂₃X₂₄WLVRRGGPSSGAPPPS-R₂₀ (SEQ ID NO: 98), or a sequence that differs from SEQ ID NO: 98 by 1 or 2 amino acid substitutions;

20 wherein

X₁₀ is Trp, dTrp or Val;

X₁₁ is Trp, dTrp or Ser; X₁₂ is Arg, Lys or Ser X₁₅ is Glu or dGlu

X₁₆ is Trp, dTrp, dGlu or Glu; X₂₃ is Ile or dIle;

X₂₄ is Ala or Glu;

25 R₁₀ is NH₂, -CO(CH₂)₁₄₋₂₀CH₃ or -CO(CH₂)₁₄₋₂₀COOH; and R₂₀ is COOH or CONH₂. In one embodiment the sequence of SEQ ID NO: 98 is provided wherein

X₁₀ is Val;

X₁₁ is Trp, dTrp or Ser; X₁₂ is Arg, Lys or Ser X₁₅ is Glu or dGlu

30 X₁₆ is dGlu or Glu; X₂₃ is Ile;

X₂₄ is Ala or Glu;

R₁₀ is -CO(CH₂)₁₄₋₂₀CH₃ or -CO(CH₂)₁₄₋₂₀COOH and

R₂₀ is COOH, optionally wherein the peptide comprises one or more substitutions of Aib at any of positions 16, 18, 19, 24, 26 or 28, relative to the native Exendin4 sequence (SEQ ID NO: 1).

35 In one embodiment a GLP-1 receptor antagonist is provided, wherein the antagonist comprises the amino acid sequence of

R₁₀-DX₁₀X₁₁X₁₂YLX₁₅X₁₆QAVREFX₂₃X₂₄WLVRRGGPSSGAPPPS-R₂₀ (SEQ ID NO: 98);

wherein

- X₁₀ is Val;
- 5 X₁₁ is Ser;
- X₁₂ is Arg;
- X₁₅ is Glu or dGlu
- X₁₆ is dGlu or Glu;
- X₂₃ is Ile;
- 10 X₂₄ is Glu; and
- R₁₀ is -CO(CH₂)₁₄₋₂₀CH₃ or -CO(CH₂)₁₄₋₂₀COOH and
- R₂₀ is COOH or CONH₂.

In one embodiment the GLP-1 antagonist peptide comprises an amino acid sequence of R₁₀-DVSSYLEEQAVREFIAWLKGGPSSGAPPPS (SEQ ID NO: 3) or an amino acid sequence that differs from SEQ ID NO: 3 by 1, 2 or 3 amino acid substitutions while retaining GLP-1 agonist activity, wherein R₁₀ is -CO(CH₂)₁₄₋₂₀CH₃ or -CO(CH₂)₁₄₋₂₀COOH linked to the N-terminal alpha amine of the amino acid sequence of SEQ ID NO: 3, and R₂₀ is COOH or CONH₂, optionally wherein R₂₀ is COOH.

In one embodiment the GLP-1 antagonist peptide comprises an amino acid sequence of DVX₁₁RYLQX₁₅X₁₆AVREFX₂₃EWLVRRGGPSSGAPPPSX₄₀-R₂₀ (SEQ ID NO: 25) wherein

- X₁₁ is Trp, dTrp or Ser;
- X₁₅ is Glu or dGlu;
- X₁₆ is Glu or dGlu;
- 25 X₂₃ is Ile, or dIle;
- X₄₀ is an acylated amino acid, optionally a Lys acylated with a C16-C18 fatty acid or diacid, optionally via a spacer; and


R₂₀ is COOH or CONH₂. Optionally, the GLP-1 antagonist of SEQ ID NO: 25 is further modified by one or more Aib substitutions at any of positions 16, 18, 19, 24, 26, or 28 relative to the numbering of the native Exendin4 sequence of SEQ ID NO: 1, or optionally a substitution of an acylated Lys at position 12. In one embodiment a peptide of SEQ ID NO: 25 is provided further comprising a substitution of an acylated Lys at position 12 and an optional substitution of Aib at position 27.

In one embodiment the GLP-1 antagonist peptide comprises an amino acid sequence of

DVX₁₁RYLEEQAVREFIEWLVRRGGPSSGAPPPSX₄₀R₂ (SEQ ID NO: 6) or
X₇X₈DVX₁₁RYLEEQAVREFIEWLVRRGGPSSGAPPPSX₄₀R₂₀ (SEQ ID


NO:26) wherein X₇ is an acylated Lys or acylated dLys, and X₈ is Gly or Sarcosine, X₁₁ is Trp or dTrp, X₄₀ is an acylated amino acid, optionally an acylated Lys, wherein the acylated Lys residues comprise a C16-C18 fatty acid or diacid covalently linked to the Lys side chain, optionally via a spacer, and R₂₀ is COOH or CONH₂. Optionally, the peptides of SEQ ID NO: 6 and SEQ ID NO: 26 can be further modified with an Aib substitution at any one of positions at any of positions 16, 18, 19, 24, 26 or 28 based on the numbering of native Exendin4 (SEQ ID NO: 1) or the peptide of SEQ ID NO: 6 is optionally substituted with an acylated Lys at position 12.

In one embodiment the GLP-1 antagonist peptide comprises an amino acid sequence of DVX₁₁RYLEEQA VREFIEWLVRGGPSSGAPPSX₄₀R₂₀ (SEQ ID NO: 6 or DVWRYLEEQA VREFIEWLVRGGPSSGAPPSX₄₀R₂₀ (SEQ ID NO: 7) or an amino acid that differs from SEQ ID NO: 6 or SEQ ID NO: 7 by 1 or 2 amino acid substitutions, wherein X₁₁ is Trp or dTrp, X₄₀ is an amino acid having an acyl group of sufficient sized to bind serum albumin with high affinity linked to the side chain of the amino acid, optionally where the acyl group is linked via a spacer, and R₂₀ is COOH or CONH₂ optionally with an Aib substitution at any one of positions 16, 18, 19, 24, 26 or 28 relative the numbering of native Exendin4 (SEQ ID NO: 1) and optionally wherein the carboxy group of the C-terminal amino acid is substituted with an amide (i.e., R₂₀ is CONH₂). In one embodiment X₄₀ is an amino acid comprising a structure of Formula I (optionally, Lys), Formula II (optionally, Ser), or Formula III (optionally, Cys), wherein each of Formulae I, II, and III, is:




wherein n = 1 to 4

[Formula I];



Wherein n = 1 to 4

[Formula II]



Wherein n = 1 to 4

[Formula III].

5

In one embodiment the GLP-1 antagonist peptide comprises an amino acid sequence of

10 DVX₁₁RYLEEQAVREFIEWLVRGGPSSGAPPSX₄₀-COOH (SEQ ID NO: 9) or

DVX₁₁RYLEEQAVREFIEWLVRGGPSSGAPPSX₄₀-NH₂ (SEQ ID NO: 10), wherein X₁₁ is Trp or dTrp, and X₄₀ is an amino acid having an acyl group linked to the side chain of the amino acid, optionally via a spacer. In one embodiment X₄₀ is an acylated Lys.

15

In accordance with one embodiment a GLP-1 receptor antagonist peptide is provided having the amino acid sequence of

DVWX₁₂YLEEQAVREFIEWLVRGGPSSGAPPSX₄₀-NH₂ (SEQ ID NO: 8), wherein

20

X₁₂ is an acylated Lys; and

X₄₀ is an acylated Lys having an amide substituting for the C-terminal carboxylic acid, wherein the acyl group of the acylated Lys is a C16-C18 acid or diacid, optionally linked via a spacer to the Lys side chain.

25

In yet another aspect, the amino acid at position 1 of any of the GLP-1 receptor antagonists disclosed herein is modified to inhibit protease degradation of the peptide. In one embodiment, inhibition of proteases is accomplished by:

30

- i. acylating the side chain of the N-terminal amino acid;
- ii. substituting the N-terminal amino acid with its D-stereoisomer;
- iii. modifying the N-terminal alpha amine, including for example, covalently linking an acetyl group to the alpha amine, or removing the alpha amine group; or
- iv. any combination of i)-iii).

In one embodiment a peptide comprising the sequence of

DVX₁₁RYLEEQAVREFIEWLVRGGPSSGAPPSX₄₀R₂ (SEQ ID NO: 6) is provided having up to 3 amino acid modifications relative to SEQ ID NO: 6, wherein X₁₁ is Trp or dTrp, X₄₀ is an acylated amino acid, and R₂₀ is COOH or CONH₂, wherein the peptide exhibits antagonist activity at the human GLP-1.

5 In one embodiment the GLP-1 receptor antagonist comprises a peptide selected from the group consisting of

DV(dW)RYLEEQAVREFIEWLVRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 27)
 DVWRYLEEQAVREFIEWLVRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 28)
 DV(dW)RYLE(Aib)QAVREFIEWLVRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 29)
 10 DVWRYLE(Aib)QAVREFIEWLVRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 30)
 DV(dW)RYLEEQ(Aib)VREFIEWLVRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 31)
 DVWRYLEEQ(Aib)VREFIEWLVRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 32)
 DV(dW)RYLEEQA(Aib)REFIEWLVRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 33)
 DVWRYLEEQA(Aib)REFIEWLVRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 34)
 15 DV(dW)RYLEEQAVREFI(Aib)WLVRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 35)
 DVWRYLEEQAVREFI(Aib)WLVRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 36)
 DV(dW)RYLEEQAVREFIEW(Aib)VRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 37)
 DVWRYLEEQAVREFIEW(Aib)VRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 38)
 DV(dW)RYLEEQAVREFIEWLV(Aib)GGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 39)
 20 DVWRYLEEQAVREFIEWLV(Aib)GGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 40)
 DV(dW)RYLEEQAV(dR)EFIEWLVRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 41)
 DVWRYLEEQAV(dR)EFIEWLVRGGPSSGAPPSX₄₀ R₂₀, (SEQ ID NO: 42),
 wherein X₄₀ is an acylated amino acid, optionally a Lys acylated with a C16-C18 fatty acid or diacid, and R₂₀ is COOH or CONH₂, wherein the peptide exhibits antagonist
 25 activity at the human GLP-1.

In one embodiment the GLP-1 receptor antagonist comprises a peptide selected from the group consisting of

R₁₀-DV(dW)RYLEEQAVREFIEWLVRGGPSSGAPPS-R₂₀, (SEQ ID NO: 100)
 R₁₀-DVWRYLEEQAVREFIEWLVRGGPSSGAPPS-R₂₀, (SEQ ID NO: 101)
 30 R₁₀-DV(dW)RYLE(Aib)QAVREFIEWLVRGGPSSGAPPS-R₂₀, (SEQ ID NO: 102)
 R₁₀-DVWRYLE(Aib)QAVREFIEWLVRGGPSSGAPPS-R₂₀, (SEQ ID NO: 103)
 R₁₀-DV(dW)RYLEEQ(Aib)VREFIEWLVRGGPSSGAPPS-R₂₀, (SEQ ID NO: 104)
 R₁₀-DVWRYLEEQ(Aib)VREFIEWLVRGGPSSGAPPS-R₂₀, (SEQ ID NO: 105)
 R₁₀-DV(dW)RYLEEQA(Aib)REFIEWLVRGGPSSGAPPS-R₂₀, (SEQ ID NO: 106)
 35 R₁₀-DVWRYLEEQA(Aib)REFIEWLVRGGPSSGAPPS-R₂₀, (SEQ ID NO: 107)
 R₁₀-DV(dW)RYLEEQAVREFI(Aib)WLVRGGPSSGAPPS-R₂₀, (SEQ ID NO: 108)
 R₁₀-DVWRYLEEQAVREFI(Aib)WLVRGGPSSGAPPS-R₂₀, (SEQ ID NO: 109)

R₁₀-DV(dW)RYLEEQAVREFIEW(Aib)VRGGPSSGAPPPS-R₂₀, (SEQ ID NO: 110)
R₁₀-DVWRYLEEQAVREFIEW(Aib)VRGGPSSGAPPPS-R₂₀, (SEQ ID NO: 111)
R₁₀-DV(dW)RYLEEQAVREFIEWLV(Aib)GGPSSGAPPPS-R₂₀, (SEQ ID NO: 112)
R₁₀ DVWRYLEEQAVREFIEWLV(Aib)GGPSSGAPPPS-R₂₀, (SEQ ID NO: 113)
R₁₀-DV(dW)RYLEEQAV(dR)EFIEWLVRGGPSSGAPPPS-R₂₀, (SEQ ID NO: 114)
R₁₀-DVWRYLEEQAV(dR)EFIEWLVRGGPSSGAPPPS-R₂₀, (SEQ ID NO: 115),
wherein R₁₀ is -CO(CH₂)₁₄₋₂₀CH₃ or -CO(CH₂)₁₄₋₂₀COOH linked to the N-terminal alpha
amine of the polypeptide, and R₂₀ is COOH or CONH₂, wherein the peptide exhibits
antagonist activity at the human GLP-1.

Additional exemplified species of the present disclosure include those listed in
Table 1:

Table 1

SEQ ID NO.	Description/cmpd registry	Sequence
1	Exendin-4	HGEGTFTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS
2	Ex-4 (9-39)a	DVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS
3	Jant4 9-40am; K40[C16]	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[C16]-OH
4		DVSRYLEEQAVREFIEWLVRGGPSSGAPPPSK
5		DX ₁₀ X ₁₁ RYLX ₁₅ X ₁₆ QAVREFX ₂₃ EWLVRGGPSSGAPPPSX ₄₀
6		DVX ₁₁ RYLEEQAVREFIEWLVRGGPSSGAPPPSX ₄₀
7		DVWRYLEEQAVREFIEWLVRGGPSSGAPPPSX ₄₀
8		DVWX ₁₂ YLEEQAVREFIEWLVRGGPSSGAPPPSX ₄₀ -NH ₂
9		DVX ₁₁ RYLEEQAVREFIEWLVRGGPSSGAPPPSX ₄₀ -COOH
10		DVX ₁₁ RYLEEQAVREFIEWLVRGGPSSGAPPPSX ₄₀ -NH ₂
11		DVX ₁₁ RYLX ₁₅ X ₁₆ QAVREFX ₂₃ EWLVRGGPSSGAPPPSK
12		DVSSYLEEQAVREFIAWLKGGPSSGAPPPSX ₄₀
13		DVSRYLEEQAVREFIEWLVRGGPSSGAPPPSX ₄₀
14	X ₇ X ₈ = dK(mPeg- γE-DiAcidC18)(N- Me-Gly)	X ₇ X ₈ DVSRYLEEQAVREFIEWLVRGGPSSGAPPPSX ₄₀

15	X ₇ X ₈ = dK(mPeg- γE-DiAcidC18)(N- iPr-Gly	X ₇ X ₈ DVSRYLEEQAVREFIEWLVRGGPSSGAPPPSX ₄₀
16	9-40AC; Jant4 (R12,E24,R28) K40[mPEG-gE- C16]	DVSRYLEEQAVREFIEWLVRGGPSSGAPPPSK[miniPEG- γE-C16]-OH
17	9-40AC, dK7(mPeg- γE(DiAcid C18))G8 R12,E24,R28, K40(mPeg-γE(C16)) (Pro-drug)	dK(mPeg-γE- DiAcidC18)GDVSRYLEEQAVREFIEWLVRGGPSSGAPPPS K[miniPEG-gE-C16]-OH
18	9-40AC, dK7(mPeg- γE(DiAcid C18)) (N-iPr- Gly8) R12,E24,R28, K40(mPeg-γE(C16)) (Pro-drug)	dK(mPeg-γE-DiAcidC18)(N-iPr- Gly)DVSRYLEEQAVREFIEWLVRGGPSSGAPPPSK[miniP EG-gE-C16]-OH
19	9-40AC, dK7(mPeg- γE(DiAcid C18)) (N-Me- Gly8) R12,E24,R28, K40(mPeg-γE(C16)) (Pro-drug)	dK(mPeg-γE-DiAcidC18)(N-Me- Gly8)DVSRYLEEQAVREFIEWLVRGGPSSGAPPPSK[miniP EG-gE-C16]-OH
20	Jant9-40am, dK7(C18diacid-gE- mPeg-K(mPeg- gE- C18discid),G8, K40(mPeg-gE-C18 diacid)	dK7(C18diacid-gE-mPeg-K(mPeg-gE- C18diacid)GDVSRYLEEQAVREFIEWLVRGGPSSGAPPPSK [miniPEG-gE-C18diacid)-NH ₂
21	Jant9-40am, dK7(C18diacid-gE- mPeg-K(mPeg-gE- C18discid),G8, K40(mPeg-gE-C16)	dK7(C18diacid-gE-mPeg-K(mPeg-gE- C18diacid)GDVSRYLEEQAVREFIEWLVRGGPSSGAPPPSK [miniPEG-gE-C16)-NH ₂

22	Jant9-40am, dK7(C18diacid-gE- mPeg-K(mPeg-gE- C18discid),N- meGly, K40(mPeg- gE-C16)	dK7(C18diacid-gE-mPeg-K(mPeg-gE-C18diacid)-N-MeGly- DVSRYLEEQA VREFIEWLVRGGPSSGAPPPSK[miniPEG- gE-C16)-NH2
23		DVX ₁₁ X ₁₂ YLX ₁₅ X ₁₆ QAX ₁₉ X ₂₀ EFX ₂₃ EWLVRGGPSSGAPPPSX ₄₀
24		DVX ₁₁ X ₁₂ YLEX ₁₆ QAVREFIEWLVRGGPSSGAPPPSX ₄₀
25		DVX ₁₁ RYLQX ₁₅ X ₁₆ AVREFX ₂₃ EWLVRGGPSSGAPPPSX ₄₀
26		X ₇ X ₈ DVX ₁₁ RYLEEQA VREFIEWLVRGGPSSGAPPPSX ₄₀ R ₂₀
27		DV(dW)RYLEEQA VREFIEWLVRGGPSSGAPPPSX ₄₀ R ₂₀
28		DVWRYLEEQA VREFIEWLVRGGPSSGAPPPSX ₄₀ R ₂₀
29		DV(dW)RYLE(Aib)QAVREFIEWLVRGGPSSGAPPPSX ₄₀ R ₂₀
30		DVWRYLE(Aib)QAVREFIEWLVRGGPSSGAPPPSX ₄₀ R ₂₀
31		DV(dW)RYLEEQA(Aib)VREFIEWLVRGGPSSGAPPPSX ₄₀ R ₂₀
32		DVWRYLEEQA(Aib)VREFIEWLVRGGPSSGAPPPSX ₄₀ R ₂₀
33		DV(dW)RYLEEQA(Aib)REFIEWLVRGGPSSGAPPPSX ₄₀ R ₂₀
34		DVWRYLEEQA(Aib)REFIEWLVRGGPSSGAPPPSX ₄₀ R ₂₀
35		DV(dW)RYLEEQA VREFI(Aib)WLVRGGPSSGAPPPSX ₄₀ R ₂₀
36		DVWRYLEEQA VREFI(Aib)WLVRGGPSSGAPPPSX ₄₀ R ₂₀
37		DV(dW)RYLEEQA VREFIEW(Aib)VRGGPSSGAPPPSX ₄₀ R ₂₀
38		DVWRYLEEQA VREFIEW(Aib)VRGGPSSGAPPPSX ₄₀ R ₂₀
39		DV(dW)RYLEEQA VREFIEWLV(Aib)GGPSSGAPPPSX ₄₀ R ₂₀
40		DVWRYLEEQA VREFIEWLV(Aib)GGPSSGAPPPSX ₄₀ R ₂₀
41		DV(dW)RYLEEQA V(dR)EFIEWLVRGGPSSGAPPPSX ₄₀ R ₂₀
42		DVWRYLEEQA V(dR)EFIEWLVRGGPSSGAPPPSX ₄₀ R ₂₀
43	9-40am; Jant4 (K27, Aib28) K40[C16]	DVSSYLEEQA VREFIAWLK(Aib)GGPSSGAPPPSK[C16]- NH2
44	9-40am; Jant4 (Aib26) K40[C16]	DVSSYLEEQA VREFIAW(Aib)VKGGPSSGAPPPSK[C16]- NH2
45	9-40am; Jant4 (Aib19) K40[C16]	DVSSYLEEQA(Aib)REFIAWLKGGPSSGAPPPSK[C16]- NH2
46	9-40am; Jant4 (Aib18) K40[C16]	DVSSYLEEQA(Aib)VREFIAWLKGGPSSGAPPPSK[C16]- NH2

47	9-40am; Jant4 K40[C16]	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[C16]-NH2
48	9-40am; Jant4 K40[(mPEG)2-gE- C16]	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[(miniPEG)2 -gE-C16]-NH2
49	9-40am; Jant4 (dE15) K40[C16]	DVSSYL(dE)EQAVREFIAWLKGGPSSGAPPPSK[C16]- NH2
50	9-40am; Jant4 (dV19) K40[C16]	DVSSYLEEQA(dV)REFIAWLKGGPSSGAPPPSK[C16]- NH2
51	9-40am; Jant4 (dI23) K40[C16]	DVSSYLEEQAVREF(dI)AWLKGGPSSGAPPPSK[C16]- NH2
52	9-40am; Jant4 K40[gE-C16]	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[gE-C16]- NH2
53	9-40am; Jant4 K40[gE2-C16]	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[gE2-C16]- NH2
54	9-40am; Jant4 K40[gE4-C16]	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[gE4-C16]- NH2
55	9-40am; Jant4 K40[gE6-C16]	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[gE6-C16]- NH2
56	9-40am; Jant4 K40[mPEG-gE- C16]	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[miniPEG- gE-C16]-NH2
57	9-40am; Jant4 K40[EP2E-C16]	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[gE- (miniPEG)2-gE-C16]-NH2
58	9-40am; Jant4 K40(P2E2-C16)	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[(miniPEG)2 -gE2-C16]-NH2
59	9-40am; Jant4 K40(PEPE-C16)	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[miniPEG- gE-miniPEG-gE-C16]-NH2
60	9-40am; Jant4 K40[PE2P-C16]	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[miniPEG- gE2-miniPEG-C16]-NH2
61	9-40am; Jant4 K40[E2P2-C16]	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[gE2- (miniPEG)2-C16]-NH2
62	9-40am; Jant4 K40[EPEP-C16]	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK[gE- miniPEG-gE-miniPEG-C16]-NH2

63	9-40am; Jant4 K40[DiAcC18]	DVSSYLEEQAVREFIAWLVKGGPSSGAPPPSK[DiAcid C18]-NH2
64	9-40am; Jant4 K40[gE2-DiAcC18]	DVSSYLEEQAVREFIAWLVKGGPSSGAPPPSK[gE2- DiAcidC18]-NH2
65	9-40am; Jant4 K40[gE4-DiAcC18]	DVSSYLEEQAVREFIAWLVKGGPSSGAPPPSK[gE4- DiAcidC18]-NH2
66	9-40am; Jant4 K40[gE6-DiAcC18]	DVSSYLEEQAVREFIAWLVKGGPSSGAPPPSK[gE6- DiAcidC18]-NH2
67	9-40am; Jant4 K40[(mPEG)2-gE- DiAcC18]	DVSSYLEEQAVREFIAWLVKGGPSSGAPPPSK[(miniPEG)2 -gE-DiAcidC18]-NH2
68	9-40am; Jant4 K40[mPEG-gE- DiAcC18]	DVSSYLEEQAVREFIAWLVKGGPSSGAPPPSK[miniPEG- gE-DiAcC18]-NH2
69	9-40am; Jant4 (R28) K40[C16]	DVSSYLEEQAVREFIAWLVRGGPSSGAPPPSK[C16]-NH2
70	9-40am; Jant4 (E24,R28) K40[C16]	DVSSYLEEQAVREFIEWLVRGGPSSGAPPPSK[C16]-NH2
71	9-40am; Jant4 (E17,R28) K40[C16]	DVSSYLEEEAVREFIAWLVRGGPSSGAPPPSK[C16]-NH2
72	9-40am; Jant4 (E17,E24,R28) K40[C16]	DVSSYLEEEAVREFIEWLVRGGPSSGAPPPSK[C16]-NH2
73	9-40am; Jant4 (R12,R28) K40[C16]	DVSRYLEEQAVREFIAWLVRGGPSSGAPPPSK[C16]-NH2
74	9-40am; Jant4 (R12,E24,R28) K40[C16]	DVSRYLEEQAVREFIEWLVRGGPSSGAPPPSK[C16]-NH2
75	9-40am; Jant4 (R12,E17,E24,R28) K40[C16]	DVSRYLEEEAVREFIEWLVRGGPSSGAPPPSK[C16]-NH2
76	Ex9 K40[C16]	DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK[C16]-NH2
77	9-40AC; Jant4 (R28) K40[mPEG- gE-C16]	DVSSYLEEQAVREFIAWLVRGGPSSGAPPPSK[miniPEG- gE-C16]-OH

78	9-40AC; Jant4 (E24,R28) K40[mPEG-gE- C16]	DVSSYLEEQAVREFIEWLVRGGPSSGAPPPSK[miniPEG- gE-C16]-OH
79	9-40AC; Jant4 (E24,R27,V28) K40[mPEG-gE- C16]	DVSSYLEEQAVREFIEWLRVGGPSSGAPPPSK[miniPEG- gE-C16]-OH
80	9-40AC; Jant4 (E24,R27,Aib28) K40[mPEG-gE- C16]	DVSSYLEEQAVREFIEWLR(Aib)GGPSSGAPPPSK[miniPEG- gE-C16]-OH
81	9-40am; Jant4 (Aib27) K40[C16]	DVSSYLEEQAVREFIAWL(Aib)KGGPSSGAPPPSK[C16]- NH2
82	9-40am; Jant4 (K26, Aib28) K40[C16]	DVSSYLEEQAVREFIAWKV(Aib)GGPSSGAPPPSK[C16]- NH2
83	9-40am; Jant4 (Aib24) K40[C16]	DVSSYLEEQAVREFI(Aib)WLVKGGPSSGAPPPSK[C16]- NH2
84	9-40am; Jant4 (Aib16) K40[C16]	DVSSYLE(Aib)QAVREFIAWLKGGPSSGAPPPSK[C16]- NH2
85	9-40am; Jant4 (dE16) K40[C16]	DVSSYLE(dE)QAVREFIAWLKGGPSSGAPPPSK[C16]- NH2
86	9-40am; Jant4 (dQ17) K40[C16]	DVSSYLEE(dQ)AVREFIAWLKGGPSSGAPPPSK[C16]- NH2
87	9-40am; Jant4 (dR20) K40[C16]	DVSSYLEEQAV(dR)EFIAWLKGGPSSGAPPPSK[C16]- NH2
88	9-40am; Jant4 (dE21) K40[C16]	DVSSYLEEQAVR(dE)FIAWLKGGPSSGAPPPSK[C16]- NH2
89	Ex9, dK7(PEG2- γE(C16)), G8	dK(Peg2-gE(C16)) GDLSKQMEEEEAVRLFIEWLKNGGPSSGAPPPS- NH2
90	Ex9-40am, K40(C18 diacid)	DL SKQMEEEEAVRLFIEWLKNGGPSSGAPPPSK(C18 diacid)-NH2
91	Ex9-40am, W11, K40(C18 diacid)	DLWKQMEEEEAVRLFIEWLKNGGPSSGAPPPSK(C18 DiAcid)-NH2
92	Ex9-40am, dW11, K40(C18 diacid)	DLdWKQMEEEEAVRLFIEWLKNGGPSSGAPPPSK(C18 diacid)-NH2

93	Ex9-40am, W11, K40(mPeg-gE-C18 diacid)	DLWKQMEEEEAVRLFIEWLKNGGPSSGAPPPSK(mPeg-gE(C18 diacid))-NH2
94	Ex9-40am, dW11,K40(mPeg-gE-C18 diacid)	DLdWKQMEEEEAVRLFIEWLKNGGPSSGAPPPSK(mPeg-gE(C18 diacid))-NH2
95	9-40am; Jant4 K40	DVSSYLEEQAVREFIAWLKGGPSSGAPPPSK-NH2

In one embodiment dimers and multimers comprising two or more GLP-1 receptor antagonist peptides of the present disclosure are prepared including homo- or hetero- multimers or homo- or hetero- dimers. Two or more GLP-1 receptor antagonist peptides can be linked together using standard linking agents and procedures known to those skilled in the art. For example, dimers can be formed between two peptides through the use of bifunctional thiol crosslinkers and bi- functional amine crosslinkers, particularly for GLP-1 receptor antagonist peptides comprising, or substituted with, cysteine, lysine, ornithine, homocysteine or acetyl phenylalanine residues. The dimer can be a homodimer or alternatively can be a heterodimer. In exemplary embodiments, the linker connecting the two (or more) analogs is PEG, e.g., a 5 kDa PEG, 20 kDa PEG. In some embodiments, the linker is a disulfide bond. For example, each monomer of the dimer may comprise a Cys residue (e.g., a terminal or internally positioned Cys) and the sulfur atom of each Cys residue participates in the formation of the disulfide bond. In exemplary aspects, each monomer of the dimer is linked via a thioether bond. In exemplary aspects, an epsilon amine of a Lys residue of one monomer is bonded to a Cys residue, which, in turn, is connected via a chemical moiety to the epsilon amine of a Lys residue of the other monomer.

In some embodiments, the monomers are connected via terminal amino acids (e.g., N-terminal or C-terminal, optionally wherein the amino acid is added to the terminus of a peptide to be dimerized), via internal amino acids, or via a terminal amino acid of at least one monomer and an internal amino acid of at least one other monomer. In some embodiments, the monomers of the multimer are attached together in a “tail-to-tail” orientation in which the C-terminal amino acids of each monomer are attached together. Alternatively, in one embodiment the multimer are attached together in a “head-to-head” orientation in which the N-terminal amino acids of each monomer are attached together.

In one embodiment the C-terminal amino acid of any of the GLP-1 antagonist peptides disclosed herein can be modified to replace the native carboxyl group with an amide. In one embodiment the C-terminal amino acid of any of the GLP-1 antagonist peptides disclosed herein comprises the native amino acid carboxyl group.

Pharmaceutical Compositions

Pharmaceutical compositions comprising any of the GLP-1 receptor antagonist peptides, dimers, multimers, or conjugates of the present disclosures (or a combination thereof) and a pharmaceutically acceptable carrier, diluent, or excipient are further
5 provided by the present disclosure. The pharmaceutical compositions are preferably sterile and suitable for parenteral administration.

In accordance with one embodiment a pharmaceutical composition is provided comprising any of the novel GLP-1 receptor antagonists disclosed herein, preferably at a purity level of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, and a
10 pharmaceutically acceptable diluent, carrier or excipient. Such compositions may contain a GLP-1 receptor antagonist as disclosed herein at a concentration of at least 0.1 - 10mg/ml, or higher. In one embodiment the pharmaceutical compositions comprise aqueous solutions that are sterilized and optionally stored within various package containers. In other embodiments the pharmaceutical compositions comprise a lyophilized
15 powder. The pharmaceutical compositions can be further packaged as part of a kit that includes a disposable device for administering the composition to a patient. The containers or kits may be labeled for storage at ambient room temperature or at refrigerated temperature. In one embodiment the pharmaceutical composition and/or kit comprises any of the GLP-1 receptor antagonists disclosed herein in combination with any existing
20 therapeutics useful for treating hypoglycemia, including but not limited to glucose supplements (eg, dextrose); glucose-elevating agents such as glucagon and glucagon analogs and inhibitors of insulin secretion (eg, diazoxide, octreotide).

In accordance with one embodiment the pharmaceutical compositions disclosed herein are contemplated for use in methods of treating or preventing conditions of
25 hypoglycemia, and more specifically treating or preventing atypical hypoglycemia, or medical conditions associated with hypoglycemia.

The compositions of the present disclosure can be administered using any standard routes of administration. Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain
30 antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The term, "parenteral" means not through the alimentary canal but by some other route such as subcutaneous, intramuscular, intraspinal, or intravenous. In one
35 embodiment a pharmaceutical composition comprising a GLP-1 receptor antagonist of the present disclosure is formulated for subcutaneous administration or intravenous administration. In one embodiment the GLP-1 receptor antagonist of the disclosure, alone or in combination with other suitable components, can be prepared as an aerosol

formulation to be administered via inhalation.

In one embodiment the composition is formulated for oral delivery by coformulation of a GLP-1 receptor antagonist of the present disclosure with an absorption enhancer, which can sufficiently augment the absorption of the peptide antagonist.

5 Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) is a delivery agent that has been reported to enhance the permeability of a diverse spectrum of molecules, including peptides, such as insulin, GLP-1, calcitonin, and other macromolecules such as heparin. In accordance with one embodiment pharmaceutical compositions are provided for oral delivery wherein the composition comprises a GLP-1 receptor antagonist of the present
10 disclosure and SNAC, optionally wherein the pharmaceutical composition is formulated as a tablet.

Acylation

In accordance with one embodiment, any of the peptides, dimers or multimers
15 disclosed herein that exhibit GLP-1 antagonist activity can be further modified to have an improved therapeutic index and an *in vivo* extended time of action when administered to a warm blooded mammal including, for example, *homo sapiens*. More particularly, in one embodiment the peptides and dimers disclosed herein are modified by the covalent linkage of an alkyl or acyl group to the side chain of an amino acid, optionally a lysine,
20 serine or cysteine, of the antagonist peptide, wherein the alkyl or acyl group is of sufficient size to bind to serum albumin with high affinity. In one embodiment the alkylated or acylated amino acid is located at the C-terminus of the GLP-1 antagonist peptide or dimer. In one embodiment the GLP-1 antagonist peptide comprises two acylated amino acids. In one embodiment one or more of the amino acids of the GLP-1
25 receptor antagonist peptide is acylated with a fatty acid or fatty diacid, optionally a C16-C18 fatty acid or C16-C18 fatty diacid. In accordance with one embodiment one or more lysine residues of the GLP-1 antagonist peptide or dimer disclosed herein is modified by the covalent linkage of a C16-C18 fatty acid or C16-C18 fatty diacid the side chain of a lysine, optionally via a spacer. In one embodiment the acylated lysine residue is the C-
30 terminal amino acid of the GLP-1 antagonist peptide. In one embodiment an acylated amino acid is present at position 40 of the GLP-1 antagonist peptide and at a second position selected from position 7 or 12. In embodiments having two or more acylated amino acids, the acylated amino acids can be the same or different, and the linked acyl group can be the same or different, provided the acyl group is of sufficient size to bind
35 serum albumin. In one embodiment the acylated amino acid is a lysine wherein the side chain is linked to a C16-C18 fatty acid or C16-C18 fatty diacid, optionally via a spacer.

In one embodiment, a C16-C18 fatty acid or C16-C18 fatty diacid is linked to the

side chain of an amino acid via a spacer, wherein the spacer comprises a miniPEG, a gamma Glu, or any multimer or combination of miniPEG and/or gamma Glu. In one embodiment any of the GLP-1 receptor antagonist peptides disclosed herein may be modified to comprise an acylated amino acid, optionally at a position selected from 7, 12 and 40, in reference to the native sequence of exendin4. In one embodiment the acylated amino acid is a lysine residue having a C16 to C18 fatty acid or C16 to C18 fatty diacid linked to the lysine side chain via a spacer comprising the structure:

$-\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_q\text{-(gamma glutamic acid)}_p\text{-}$

wherein k is an integer selected from 2, 4, 6 or 8 and p and q are independently an integer selected from 1 or 2. In one embodiment the spacer is selected from the group consisting of

$-\text{(gamma glutamic acid)}_2\text{-[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_2\text{-(gamma glutamic acid)}_2\text{-}$, or

$-\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_q\text{-(gamma glutamic acid)}_p\text{-[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_q\text{-}$

$\text{(gamma glutamic acid)}_p\text{-}$, or

$-\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_2\text{-(gamma glutamic acid)}_2\text{-}$, or

$-\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_2\text{-(gamma glutamic acid)}_2\text{-[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_2\text{-}$,

or

$-\text{(gamma glutamic acid)}_2\text{-[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_2\text{-}$, or

$-\text{(gamma glutamic acid)}_2\text{-[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_2\text{-(gamma glutamic acid)}_p\text{-}$

$\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_2\text{-}$, or gamma glutamic acid, or a gamma glutamic acid-gamma glutamic acid dipeptide, or a gamma glutamic acid-[COCH₂(OCH₂CH₂)_kNH]-gamma glutamic acid, wherein

k is an integer selected from the range of 1-8; and

q and p are independently an integer selected from the range of 1-8, optionally

wherein k is 2 and q and p are independently 1 or 2. In one embodiment the spacer is

$-\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_q\text{-(gamma glutamic acid)}_p\text{-}$, wherein

k is an integer selected from the range of 1-4; and

q and p are independently an integer selected from the range of 1-4, optionally

wherein k is 2 and q and p are independently 1 or 2, optionally wherein k is 2 and q and p are both 1.

In one embodiment the GLP-1 receptor antagonist peptide comprises an acylated Lys, optionally located at the C-terminus of the peptide, wherein the side chain of the Lys is acylated with a C16-C18 diacid, via a spacer comprising the structure: -

$\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_q\text{-(gamma glutamic acid)}_p\text{-}$, wherein

k is an integer selected from the range of 1-4; and

q and p are independently an integer selected from the range of 1-4, optionally wherein k is 2 and q and p are independently 1 or 2, optionally wherein k is 2 and q and p are both 1.

In one embodiment the side chain of the acylated Lys comprises the structure -
 $[\text{COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH}]_q$ -(gamma glutamic acid)_p-COC₁₆H₃₂CO₂H, wherein k is 2 and p
 and q are independently 1 or 2. In one embodiment a GLP-1 receptor antagonist is
 provided comprising the sequence of

5 DV(dW)RYLEEQA VREFIEWLVRGGPSSGAPPSX₄₀R₂₀, (SEQ ID NO: 27) or
 DVWRYLEEQA VREFIEWLVRGGPSSGAPPSX₄₀R₂₀, (SEQ ID NO: 28),
 wherein

R₂₀ is COOH or CONH₂ and X₄₀ is a Lys acylated with -[COCH₂(OCH₂CH₂)_kNH]_q-
 (gamma glutamic acid)_p-COC₁₄H₂₈CO₂H or -[COCH₂(OCH₂CH₂)_kNH]_q-(gamma
 10 glutamic acid)_p-COC₁₆H₃₂CO₂H, wherein k is 2 and p and q are independently 1 or 2.

Conjugates

In some embodiments any one of the GLP-1 antagonist peptides disclosed herein
 is conjugated to an immunoglobulin or portion thereof (e.g. variable region, CDR, or Fc
 15 region). Known types of immunoglobulins (Ig) include IgG, IgA, IgE, IgD or IgM. The
 Fc region is a C-terminal region of an Ig heavy chain, which is responsible for binding to
 Fc receptors that carry out activities such as recycling (which results in prolonged half-
 life), antibody dependent cell-mediated cytotoxicity (ADCC), and complement dependent
 cytotoxicity (CDC).

20 In some embodiments, any one of the GLP-1 antagonist peptides disclosed herein
 is conjugated to a hydrophilic moiety. Hydrophilic moieties can be covalently linked to
 the GLP-1 antagonist peptide under any suitable conditions used to react a protein with an
 activated polymer molecule. Activating groups which can be used to link the water
 soluble polymer to one or more proteins include without limitation sulfone, maleimide,
 25 sulfhydryl, thiol, triflate, tresylate, aziridine, oxirane, 5-pyridyl, and alpha-halogenated
 acyl group (e.g., alpha-iodo acetic acid, alpha-bromoacetic acid, alpha-chloroacetic acid).
 If attached to the peptide by reductive alkylation, the polymer selected should have a
 single reactive aldehyde so that the degree of polymerization is controlled. See, for
 example, Kinstler et al., *Adv. Drug. Delivery Rev.* 54: 477-485 (2002); Roberts et al., *Adv.*
 30 *Drug Delivery Rev.* 54: 459-476 (2002); and Zalipsky et al., *Adv. Drug Delivery Rev.* 16:
 157-182 (1995).

Suitable hydrophilic moieties include polyethylene glycol (PEG), polypropylene
 glycol, polyoxyethylated polyols (e.g., POG), polyoxyethylated sorbitol, polyoxyethylated
 glucose, polyoxyethylated glycerol (POG), polyoxyalkylenes, polyethylene glycol
 35 propionaldehyde, copolymers of ethylene glycol/propylene glycol, monomethoxy-
 polyethylene glycol, mono-(C1-C10) alkoxy-or aryloxy-polyethylene glycol,
 carboxymethylcellulose, polyacetals, polyvinyl alcohol (PVA), polyvinyl pyrrolidone,

poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, poly (beta.-amino acids) (either homopolymers or random copolymers), poly(n-vinyl pyrrolidone)polyethylene glycol, propylene glycol homopolymers (PPG) and other polyakylene oxides, polypropylene oxide/ethylene oxide copolymers, colonic acids or other polysaccharide polymers, Ficoll or dextran and mixtures thereof. Dextrans are polysaccharide polymers of glucose subunits, predominantly linked by α 1-6 linkages. Dextran is available in many molecular weight ranges, e.g., about 1 kD to about 100 kD, or from about 5, 10, 15 or 20 kD to about 20, 30, 40, 50, 60, 70, 80 or 90 kD. In one embodiment the hydrophilic moiety, e.g., polyethylene glycol chain, has a molecular weight selected from the range of about 500 to about 40,000 Daltons. In some embodiments the hydrophilic moiety is a polyethylene glycol chain having a molecular weight selected from the range of about 500 to about 5,000 Daltons, or about 1,000 to about 5,000 Daltons. In another embodiment the hydrophilic moiety, e.g., polyethylene glycol chain, has a molecular weight of about 10,000 to about 20,000 Daltons.


In one embodiment a conjugate derivative of the peptide of SEQ ID NO: 5 or SEQ ID NO: 23 is provided wherein a dipeptide is covalently linked via a peptide bond to the N-terminus of the peptide of SEQ ID NO: 5 or SEQ ID NO: 23, optionally wherein one of the amino acids of the dipeptide is an acylated amino acid. In one embodiment the dipeptide has the structure of X_7X_8 , wherein X_7 is an acylated amino acid and X_8 is any amino acid, optionally wherein X_7 is an acylated Lys or dLys and X_8 is Gly or a C1-C4 N-alkylated Gly, optionally wherein X_7 is a Lys or dLys acylated with a C14-C20 fatty acid or fatty diacid and X_8 is Gly or a C1-C4 N-alkylated Gly (optionally Gly or Sarcosine), optionally wherein X_7 is a Lys acylated with a C14-C20 fatty acid or fatty diacid via any of the spacers disclosed herein and X_8 is a C1-C4 N-alkylated Gly (optionally Gly or Sarcosine).

In accordance with one embodiment a conjugate derivative of any of the GLP-1 receptor antagonist peptides is provided wherein a self-cleaving dipeptide is covalently bound to an amino acid side chain amine or the N-terminal alpha amine of a GLP-1 antagonist peptide disclosed herein via an amide bond. In one embodiment the self-cleaving dipeptide is covalently bound to the N-terminal alpha amine of the GLP-1 antagonist peptide.

In exemplary aspects, the self-cleaving dipeptide comprises the structure: A-B wherein A is an amino acid or a hydroxy acid; and B is an N-alkylated amino acid linked to the GLP-1 antagonist peptide through an amide bond between A-B and an amine of the GLP-1 antagonist peptide, optionally wherein the chemical cleavage half-life ($t_{1/2}$) of A-B from the GLP-1 antagonist peptide is at least about 1 hour to about 1 week in PBS under physiological conditions. As used herein the term "hydroxy acid" refers to an amino

acid that has been modified to replace the alpha carbon amino group with a hydroxyl group.

In some embodiments the self-cleaving dipeptide has the general structure of:



5 wherein

R₁, R₂, R₄ and R₈ are independently selected from the group consisting of H, C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, (C₁-C₁₈ alkyl)OH, (C₁-C₁₈ alkyl)SH, (C₂-C₃ alkyl)SCH₃, (C₁-C₄ alkyl)CONH₂, (C₁-C₄ alkyl)COOH, (C₁-C₄ alkyl)NH₂, (C₁-C₄ alkyl)NHC(NH₂⁺)NH₂, (C₀-C₄ alkyl)(C₃-C₆ cycloalkyl), (C₀-C₄ alkyl)(C₂-C₅ heterocyclic), (C₀-C₄ alkyl)(C₆-C₁₀ aryl)R₇, (C₁-C₄ alkyl)(C₃-C₉ heteroaryl), and C₁-C₁₂ alkyl(W₁)C₁-C₁₂ alkyl, wherein W₁ is a heteroatom selected from the group consisting of N, S and O;

R₃ is selected from the group consisting of C₁-C₁₈ alkyl, (C₁-C₁₈ alkyl)OH, (C₁-C₁₈ alkyl)NH₂, (C₁-C₁₈ alkyl)SH, (C₀-C₄ alkyl)(C₃-C₆)cycloalkyl, (C₀-C₄ alkyl)(C₂-C₅ heterocyclic), (C₀-C₄ alkyl)(C₆-C₁₀ aryl)R₇, and (C₁-C₄ alkyl)(C₃-C₉ heteroaryl) or R₄ and R₃ together with the atoms to which they are attached form a pyrrolidine ring;


R₅ is NHR₆ or OH:

R₆ is H, C₁-C₈ alkyl; and

R7 is selected from the group consisting of H and OH

wherein the chemical cleavage half-life ($t_{1/2}$) of A-B from said GLP-1 antagonist is at least about 1 hour to about 1 week in PBS under physiological conditions. In one embodiment the dipeptide A-B is covalently linked to the N- terminal alpha amine of the GLP-1 antagonist amino acid sequence.

In one embodiment the self-cleaving dipeptide has the general structure of:



25 wherei

R₁ and R₈ are independently H or C₁-C₈ alkyl;

R₂ and R₄ are independently selected from the group consisting of H, C₁-C₈ alkyl, (C₁-C₄ alkyl)OH, (C₁-C₄ alkyl)SH, (C₂-C₃ alkyl)SCH₃, (C₁-C₄ alkyl)CONH₂, (C₁-C₄

alkyl)COOH, (C₁-C₄ alkyl)NH₂, and (C₁-C₄ alkyl)(C₆ aryl)R₇;

R₃ is C₁-C₆ alkyl;


R₅ is NH₂; and

R₇ is selected from the group consisting of hydrogen, and OH.

5 In accordance with one embodiment any of the GLP-1 antagonist peptides and dimers disclosed herein can be further modified by linkage to a self-cleaving dipeptide wherein an amino acid of the dipeptide is acylated with a fatty-acyl group of sufficient size to bind serum albumin with high affinity.

10 In one embodiment amino acid "A" of the self-cleaving dipeptide "A-B" is a lysine residue acylated with a C₁₆-C₃₀ fatty acid or C₁₆-C₃₀ diacid. In one embodiment A and B are selected to provide a chemical cleavage half-life (t_{1/2}) of A-B from the GLP-1 antagonist peptides or dimers disclosed herein of at least about 24 hours to about 240 hours, about 48 hours to about 168 hours, or about 48 to about 120 hours, or about 70 to about 100 hours in standard PBS solution under physiological conditions.

15 In one embodiment the self-cleaving dipeptide has the general structure of :



wherein

20 R₁, comprises a side chain selected from the group consisting of C₁-C₈ alkyl, (C₁-C₄ alkyl)OH, (C₁-C₄ alkyl)SH, (C₁-C₄ alkyl)COOH, and (C₁-C₄ alkyl)NH₂, optionally wherein a C₁₆-C₁₈ fatty acid or C₁₆-C₁₈ diacid is covalently linked to said side chain, optionally via any of the spacers disclosed herein, including spacers selected from the group consisting of a gamma glutamic acid, a gamma glutamic acid- gamma glutamic acid dipeptide, -[COCH₂(OCH₂CH₂)_kNH]_q-(gamma glutamic acid)_p, and a gamma glutamic acid-[COCH₂(OCH₂CH₂)_kNH]_q-gamma glutamic acid, wherein

25 k is an integer selected from the range of 1-8; and


q and p are independently an integer selected from the range of 1-8, optionally wherein k is 2 and q and p are independently 1 or 2;

R₂, R₄ and R₈ are independently H, or C₁-C₄ alkyl;

R₃ is C₁-C₆ alkyl; and

30 R₅ is NH₂.

In one embodiment the self-cleaving dipeptide has the general structure of :



wherein


R₁ is H, C₁-C₄ alkyl, (C₁-C₄ alkyl)OH or (C₁-C₄ alkyl)NH₂; R₂ is H,

R₃ is C₁-C₄ alkyl;

5 R₄ is H or C₁-C₄ alkyl; R₅ is NH₂; and


R₈ is hydrogen.

In accordance with one embodiment the self-cleaving dipeptide A-B comprises an acylated amino acid residue as “A” and an N-alkylated Gly residue as “B”, wherein the “B” amino acid is linked to the N-terminal alpha amine of the GLP- 1 receptor antagonist peptide via an amide bond, optionally wherein said Lys residue is in the D-conformation. In one embodiment the acylated amino acid “A” of the A-B dipeptide is an amino acid having the general structure of



15 wherein n is an integer selected from the range of 1-4 and R₅₀ is selected from the group consisting of NH-CO(CH₂)₁₄₋₂₀COOH, NH-[spacer]-CO(CH₂)₁₄₋₂₀COOH, S(CH₂)₁₄₋₂₀COOH and S-[spacer]-CO(CH₂)₁₄₋₂₀COOH, wherein the [spacer] is any of the spacers disclosed herein. In one embodiment the acylated amino acid of A is independently selected from lysine, d-lysine, ornithine, cysteine or homocysteine wherein the side chain of said acylated amino acid is covalently linked to a C16-C22 fatty acid or C16-C22 diacid optionally through a spacer comprising an amino acid or dipeptide. In one embodiment the spacer comprises a gamma glutamic acid. In one embodiment the spacer comprises multiple units of gamma glutamic acid and miniPeg polymers in any combination. In one embodiment the optional spacer comprises two gamma glutamic acids, optionally wherein the two gamma glutamic acids are joined to one another via an intervening functionalized miniPEG polymer, [COCH₂(OCH₂CH₂)_kHN]_q, wherein k and q are each integers independently selected from 1, 2, 3, 4, 5, 6, 7 or 8.


In one embodiment the self-cleaving dipeptide has the general structure of :



wherein

- 5 R1 is (C4 alkyl)NH₂ or (C4 alkyl)NH(mPeg-γE-diacid)-C18;
 R2, R4 and R8 are each H;
 R3 is C1-C4 alkyl; and
 R5 is NH₂, optionally wherein the first amino acid of the self-cleaving
 dipeptide is in the D-conformation.


- 10 In one embodiment the GLP-1 antagonist peptides and dimers disclosed herein are
 covalently linked to a self-cleaving dipeptide of the structure:



wherein

- 15 R1, is a side chain selected from the group consisting of C1-C18 alkyl, (C1-
 C4 alkyl)OH, (C1-C4 alkyl)SH, (C1-C4 alkyl)COOH, and (C1-C4 alkyl)NH₂, optionally
 wherein a C16-C20 fatty acid or a C16 -C20 diacid is covalently linked to said side chain;
 R2, R4 and R8 are independently H, or C1-C4 alkyl;
 R3 is C1-C4 alkyl, or R4 and R3 together with the atoms to which they are
 attached form a pyrrolidine ring; and
 20 R5 is NH₂, with the proviso that when R4 and R3 together with the atoms
 to which they are attached form a pyrrolidine ring, R2 is not H.

In a further embodiment the self-cleaving dipeptide has the structure of



wherein R1, is (C1-C4 alkyl)NH-CO(CH₂)₁₄₋₂₀CH₃, (C1-C4 alkyl)NH-[spacer]-

CO(CH₂)₁₄₋₂₀CH₃, (C₁-C₄ alkyl)NH-CO(CH₂)₁₄₋₂₀COOH or (C₁-C₄ alkyl)NH-[spacer]-CO(CH₂)₁₄₋₂₀COOH; R₂ and R₈ are each H; R₄ is H or CH₃; R₃ is C₁-C₄ alkyl and R₅ is NH₂, optionally wherein the first amino acid of the self-cleaving dipeptide is an amino acid in the D-stereochemical configuration and the spacer is selected from any of the spacers disclosed herein. In one embodiment R₂, R₄ and R₈ are each H. In

one embodiment R₁ is (C₁-C₄ alkyl)NH-CO(CH₂)₁₆COOH or (C₁-C₄ alkyl)NH-[spacer]-CO(CH₂)₁₆COOH, R₂, R₄ and R₈ are each H and R₃ is C₁-C₄ alkyl, optionally CH₃, optionally wherein the spacer comprises the structure:

-[COCH₂(OCH₂CH₂)_kNH]_q-(gamma glutamic acid)_p-

wherein k is 2, and p and q are independently an integer selected from 1 or 2.

In accordance with one embodiment the self-cleaving dipeptide comprises an acylated amino acid as the first amino acid, wherein the side chain of the acylated amino acid is acylated with a C₁₆-C₂₀ fatty acid or C₁₆-C₂₀ diacid, optionally wherein the acylated amino acid is selected from C₁₆-C₂₀ acylated lysine, C₁₆-C₂₀ acylated ornithine, C₁₆-C₂₀ acylated cysteine and C₁₆-C₂₀ acylated homocysteine, optionally wherein the acylated amino acid of the dipeptide is a C₁₆-C₂₀ acylated Lys, optionally wherein the first amino acid of the self-cleaving dipeptide is an amino acid in the D-stereochemical configuration.

EMBODIMENTS

In accordance with embodiment 1, a GLP-1 receptor antagonist is provided, wherein said antagonist comprises the amino acid sequence of R₁₀-DVX₁₁X₁₂YLX₁₅X₁₆QAX₁₉X₂₀EFX₂₃EWLVRRGGPSSGAPPSX₄₀-R₂₀ SEQ ID NO: 23), wherein

R₁₀ is NH₂ or an N-terminal extension of 1 or 2 amino acids, wherein one of the amino acids of the N-terminal extension is acylated with a C₁₄-C₂₀ fatty acid or diacid, optionally via a spacer, optionally wherein R₁₀ is a dipeptide of the structure: X₇X₈, wherein X₇ is an acylated amino acid, optionally acylated Lys or acylated dLys, and X₈ is Gly or a C₁-C₄ N-alkylated Gly;

X₁₁ is Trp, dTrp or Ser;

X₁₂ is Arg or an acylated amino acid, optionally acylated Lys;

X₁₅ is Glu or dGlu;

X₁₆ is Glu, dGlu, Asp, homoglutamic acid or homocysteic acid;

X₁₉ is Val, cyclopropane, cyclopentane, cyclohexane or phenyl glycine;

X₂₀ is Arg, homolysine or citrulline;

X₂₃ is Ile, or dIle; and

X₄₀ is an acylated amino acid, optionally an acylated Lys; and

R₂₀ is COOH or CONH₂, optionally wherein 1, 2 or 3 amino acids selected from positions 7, 10, 13, or 16 are substituted with Trp or dTrp, with the proviso that when one of X₁₀ or X₁₁ is Trp or dTrp then the other is not Trp or dTrp and that R₁₀ and X₁₂ cannot both comprise an acylated amino acid; optionally wherein 1, 2 or 3 amino acids at any of positions 16, 18, 19, 24, 26, or 28 are substituted with Aib.

In accordance with embodiment 2 a GLP-1 antagonist of embodiment 1 is provided wherein said antagonist comprises the amino acid sequence of R₁₀-DVX₁₁X₁₂YLX₁₅X₁₆QAX₁₉X₂₀EFX₂₃EWLVRGPGSSGAPPSX₄₀-R₂₀ SEQ ID NO: 23), wherein

R₁₀ is NH₂ or X₇X₈, wherein X₇ is an amino acid acylated with a C14-C20 fatty acid or diacid, optionally via a spacer and X₈ is Gly or a C1-C4 N-alkylated Gly;

X₁₁ is Trp, dTrp or Ser;

X₁₂ is Arg or an acylated amino acid, optionally acylated Lys;

X₁₅ is Glu or dGlu;

X₁₆ is Glu, dGlu, Asp, homoglutamic acid or homocysteic acid;

X₁₉ is Val, cyclopropane, cyclopentane, cyclohexane or phenyl glycine;

X₂₀ is Arg, homolysine or citrulline;

X₂₃ is Ile, or dIle; and

X₄₀ is an acylated amino acid, optionally an acylated Lys; and

R₂₀ is COOH or CONH₂, optionally wherein 1, 2 or 3 amino acids at any of positions 16, 18, 19, 24, 26, or 28 are substituted with Aib.

In accordance with embodiment 3 a GLP-1 antagonist of embodiment 1 or 2 is provided wherein each acylated amino acid of the GLP-1 antagonist is an acylated Lys.

In accordance with embodiment 4 a GLP-1 antagonist of any one of embodiments 1-3 is provided wherein X₇ is an acylated Lys and X₁₂ is Arg.

In accordance with embodiment 5 a GLP-1 antagonist of any one of embodiments 1-3 is provided wherein R₁₀ is NH₂ and X₁₂ is an acylated Lys.

In accordance with embodiment 6 a GLP-1 antagonist of any one of embodiments 1-3 is provided wherein X₇ is NH₂ and X₁₂ is Arg.

In accordance with embodiment 7 a GLP-1 antagonist of embodiment 1 is provided wherein the antagonist comprises an amino acid sequence selected from any one of SEQ ID NO: 5 through SEQ ID NO: 96, or any combination thereof.

In accordance with embodiment 8 a GLP-1 antagonist of any one of embodiments 1-7 is provided wherein the acylated amino acids of said GLP-1 antagonist are independently a Lys residue acylated with a C16-C18 fatty acid or C16-C18 fatty diacid directly linked to the Lys side chain or optionally via a spacer comprising a

(i) gamma glutamic acid,

- (ii) miniPEG polymer: $-(\text{COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH})-$, wherein k is 2, 4, 6 or 8,
- (iii) or any multiplicity or combination of i) and/or ii).

In accordance with embodiment 9 a GLP-1 antagonist of any one of embodiments 1-8 is provided wherein said antagonist comprises the amino acid sequence of

5 DX₁₀X₁₁RYLX₁₅X₁₆QAVREFX₂₃EWLVRGGPSSGAPPPSX₄₀R₂₀ (SEQ ID NO: 5), wherein

X₁₀ is Trp, dTrp or Val;

X₁₁ is Trp, dTrp or Ser;

X₁₅ is Glu or dGlu

10 X₁₆ is Trp, dTrp, dGlu or Glu;

X₂₃ is Ile or dIle;

X₄₀ is an acylated amino acid; and

R₂₀ is COOH or CONH₂, optionally wherein the peptide comprises one or more substitutions of Aib at any of positions 16, 18, 19, 24, 26 or 28, or optionally a substitution of an acylated Lys at position 12, wherein said position number is relative to the native Exendin4 amino acid sequence.

15 In accordance with embodiment 10 a GLP-1 antagonist of any one of embodiments 1-9 is provided wherein X₁₁ is Trp or dTrp.

20 In accordance with embodiment 11 a GLP-1 antagonist of any one of embodiments 1-10 is provided wherein an amino acid at position at any of positions 16, 18, 19, 24, 26 or 28 of SEQ ID NO: 5 is substituted with Aib, optionally wherein an Aib is substituted at position 18.

In accordance with embodiment 12 a GLP-1 antagonist of any one of embodiments 1-11 is provided wherein the amino acid at position 12 is substituted with an acylated Lys.

25 In accordance with embodiment 13 a GLP-1 antagonist of any one of embodiments 1-11 is provided wherein

X₁₅ is dGlu;

X₁₆ is Glu; and

X₂₃ is Ile.

30 In accordance with embodiment 14 a GLP-1 antagonist of any one of embodiments 1-11 is provided wherein

X₁₅ is Glu;


X₁₆ is Glu; and

X₂₃ is Ile.

35 In accordance with embodiment 15 a GLP-1 antagonist of any one of embodiments 1-14 is provided wherein X₄₀ is an amino acid having an acyl group linked to the side chain of the amino acid, optionally via a spacer.

In accordance with embodiment 16 a GLP-1 antagonist of any one of
embodiments 1-15 is provided wherein X_{40} is an amino acid comprising a structure of
Formula I (optionally, Lys), Formula II (optionally, Cys), or Formula III (optionally, Ser),
wherein each of Formulae I, II, and III, is:


5



10

wherein $n = 1$ to 4


[Formula I];



15

wherein $n = 1$ to 4

[Formula II]; and



wherein $n = 1$ to 4

[Formula III].

20

In accordance with embodiment 17 a GLP-1 antagonist of any one of
embodiments 1-16 is provided wherein X_{40} is an acylated lysine.

25

In accordance with embodiment 18 a GLP-1 antagonist of any one of
embodiments 1-17 is provided wherein the acyl group of the acylated amino acid is
selected from $(\text{C}_1\text{-C}_4 \text{ alkyl})\text{NH-CO}(\text{CH}_2)_{14-20}\text{CH}_3$, $(\text{C}_1\text{-C}_4 \text{ alkyl})\text{NH-}[\text{spacer}]\text{-CO}(\text{CH}_2)_{14-20}\text{CH}_3$,
 $(\text{C}_1\text{-C}_4 \text{ alkyl})\text{NH-CO}(\text{CH}_2)_{14-20}\text{COOH}$ or $(\text{C}_1\text{-C}_4 \text{ alkyl})\text{NH-}[\text{spacer}]\text{-CO}(\text{CH}_2)_{14-20}\text{COOH}$.

In accordance with embodiment 19 a GLP-1 antagonist of any one of
embodiments 1-18 is provided wherein the acyl group of the acylated amino acid is

covalently linked to the amino acid side chain of the acylated amino acid via a spacer.

In accordance with embodiment 20 a GLP-1 antagonist of any one of embodiments 1-19 is provided wherein the spacer is an amino acid or dipeptide.

5 In accordance with embodiment 21 a GLP-1 antagonist of any one of embodiments 1-20 is provided wherein the spacer comprises a

- (i) gamma glutamic acid,
- (ii) minipeg polymer: $-\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}-$, wherein k is 2, 4, 6 or 8,
- (iii) or any multiplicity or combination of i) and/or ii).

10 In accordance with embodiment 22 a GLP-1 antagonist of any one of embodiments 1-11 is provided wherein the acylated amino acid is linked to a C16 to C18 fatty acid or C16 to C18 fatty diacid, optionally wherein the acid or diacid is linked via a spacer comprising the structure:

$-(\text{gamma glutamic acid})_p-\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_q-(\text{gamma glutamic acid})_n-$

or

15 $-\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_q-(\text{gamma glutamic acid})_p-\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_m-$;
wherein k is an integer selected from 2, 4 or 8, m and n are independently an integer selected from 0, 1 or 2, and p and q are independently an integer selected from 1, 2, 4 or 8.

20 In accordance with embodiment 23 a GLP-1 antagonist of any one of embodiments 1-22 is provided wherein the acylated amino acid is Lys having a C16 to C18 fatty acid linked to the lysine side chain via a spacer comprising the structure:

$-\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_q-(\text{gamma glutamic acid})_p-$

wherein k is 2, and p and q are independently an integer selected from 1 or 2.

25 In accordance with embodiment 24 a GLP-1 antagonist of any one of embodiments 1-23 is provided wherein

X_{11} is Trp or dTrp;

X_{15} is Glu or dGlu;

X_{16} is Glu or dGlu;

X_{23} is Ile or dIle; and


30 X_{40} is Lys acylated with a C16 or C18 diacid, optionally wherein the diacid is linked via a spacer comprising the structure:

$-\text{[COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH]}_q-(\text{gamma glutamic acid})_p-$

wherein k is 2, and p and q are independently an integer selected from 1 or 2.

35 In accordance with embodiment 25 a GLP-1 antagonist of any one of embodiments 1-24 is provided wherein R_{20} is CONH_2 .

In accordance with embodiment 26 a derivative of the GLP-1 antagonist of any one of the claims 9-25 is provided further comprising a dipeptide A-B:



linked to said GLP-1 antagonist through an amide bond wherein

R₁, R₂, R₄ and R₈ are independently selected from the group consisting of H, C₁-C₁₈ alkyl, C₂-C₁₈ alkenyl, (C₁-C₁₈ alkyl)OH, (C₁-C₁₈ alkyl)SH, (C₂-C₃ alkyl)SCH₃, (C₁-C₄ alkyl)CONH₂, (C₁-C₄ alkyl)COOH, (C₁-C₄ alkyl)NH₂, (C₁-C₄ alkyl)NHC(NH₂⁺)NH₂, (C₀-C₄ alkyl)(C₃-C₆ cycloalkyl), (C₀-C₄ alkyl)(C₂-C₅ heterocyclic), (C₀-C₄ alkyl)(C₆-C₁₀ aryl)R₇, (C₁-C₄ alkyl)(C₃-C₉ heteroaryl), and C₁-C₁₂ alkyl(W₁)C₁-C₁₂ alkyl, wherein W₁ is a heteroatom selected from the group consisting of N, S and O;

R₃ is selected from the group consisting of C₁-C₁₈ alkyl, (C₁-C₁₈ alkyl)OH, (C₁-C₁₈ alkyl)NH₂, (C₁-C₁₈ alkyl)SH, (C₀-C₄ alkyl)(C₃-C₆ cycloalkyl), (C₀-C₄ alkyl)(C₂-C₅ heterocyclic), (C₀-C₄ alkyl)(C₆-C₁₀ aryl)R₇, and (C₁-C₄ alkyl)(C₃-C₉ heteroaryl) or R₄ and R₃ together with the atoms to which they are attached form a pyrrolidine ring;

R₅ is NHR₆ or OH;

R₆ is H, C₁-C₈ alkyl; and

R₇ is selected from the group consisting of H and OH

wherein the chemical cleavage half-life ($t_{1/2}$) of A-B from said GLP-1 antagonist is at least about 1 hour to about 1 week in PBS under physiological conditions.

In accordance with embodiment 27 a GLP-1 antagonist of embodiments 26 is provided wherein the dipeptide A-B is covalently linked to the N-terminal alpha amine of the GLP-1 antagonist amino acid sequence.

In accordance with embodiment 28 a GLP-1 antagonist of any one of embodiments 26-27 is provided wherein

R₁ and R₈ are independently H or C₁-C₈ alkyl;

R₂ and R₄ are independently selected from the group consisting of H, C₁-C₈ alkyl, (C₁-C₄ alkyl)OH, (C₁-C₄ alkyl)SH, (C₂-C₃ alkyl)SCH₃, (C₁-C₄ alkyl)CONH₂, (C₁-C₄ alkyl)COOH, (C₁-C₄ alkyl)NH₂, and (C₁-C₄ alkyl)(C₆ aryl)R₇;

R₃ is C₁-C₆ alkyl;

R₅ is NH₂; and

R₇ is selected from the group consisting of hydrogen, and OH.

In accordance with embodiment 29 a GLP-1 antagonist of any one of embodiments 26-27 is provided wherein

R₁, comprises a side chain selected from the group consisting of C₁-C₈ alkyl, (C₁-

- C₄ alkyl)OH, (C₁-C₄ alkyl)SH, (C₁-C₄ alkyl)COOH, and (C₁-C₄ alkyl)NH₂, optionally wherein a C₁₆-C₃₀ fatty acid or C₁₆-C₃₀ diacid is covalently linked to said side chain, optionally via a spacer selected from the group consisting of a gamma glutamic acid, a gamma glutamic acid-gamma glutamic acid dipeptide, and a gamma glutamic acid-
- 5 [COCH₂(OCH₂CH₂)_kNH]_q-gamma glutamic acid, wherein
- k is an integer selected from the range of 1-8; and
- q is an integer selected from the range of 1-8, optionally wherein k is 2 and q is selected from the range of 1-8;
- 10 R₂, R₄ and R₈ are independently H, or C₁-C₄ alkyl;
- R₃ is C₁-C₆ alkyl; and
- R₅ is NH₂.
- In accordance with embodiment 30 a GLP-1 antagonist of any one of embodiments 26-29 is provided wherein
- 15 R₁ is H, C₁-C₄ alkyl, (C₁-C₄ alkyl)OH or (C₁-C₄ alkyl)NH₂;
- R₂ is H,
- R₃ is C₁-C₄ alkyl;
- R₄ is H, or C₁-C₄ alkyl;
- R₅ is NH₂; and
- R₈ is hydrogen.
- 20 In accordance with embodiment 31 a GLP-1 antagonist of any one of embodiments 26-30 is provided wherein said dipeptide A-B comprises an acylated Lys residue and an N-alkylated Gly residue, wherein said Lys and N-alkylated Gly residues are linked via a peptide bond, optionally wherein said Lys residue is in the D-conformation.
- 25 In accordance with embodiment 32 a GLP-1 antagonist of any one of embodiments 26-30 is provided wherein
- R₁ is (C₄ alkyl)NH₂ or (C₄ alkyl)NH(mPeg-γE-diacid)-C₁₈;
- R₂, R₄ and R₈ are each H;
- R₃ is C₁-C₄ alkyl; and R₅ is NH₂;
- 30 R₅ is an amine.
- In accordance with embodiment 33 a pharmaceutical composition comprising a GLP-1 antagonist or derivatives of any one of claims 1-32 and a pharmaceutically acceptable carrier, diluent, or excipient is provided.
- 35 In accordance with embodiment 34 a method of treating a patient suffering from atypical hypoglycemia is provided wherein said method comprises the step of administering to a patient in need thereof a pharmaceutical composition of embodiment 33 in an amount effective to elevate blood glucose levels.

EXAMPLE 1

Ex-4 (9-39)a (SEQ ID NO: 2) is an established antagonist of the GLP-1 receptor. However, its use as a therapeutic agent in humans is limited due to its nonhuman origin and its relatively short *in vivo* duration of action. Comparable N-terminal shortening of human GLP-1 lessens agonism but does not provide a high potency antagonist. Through a series of GLP-1/Ex-4 hybrid peptides, the minimal structural changes required to generate a pure GLP-1- based antagonist were identified as Glu16, Val19, and Arg20, yielding an antagonist of approximately 3-fold greater *in vitro* potency compared with Ex-4 (9-39)a. Site-specific acylation of the human-based antagonist yielded a peptide “9-40 Jant4 K₄₀[C16] (SEQ ID NO: 3) of increased potency as a GLP-1 receptor antagonist and 10-fold greater selectivity relative to the GIP receptor (Patterson, et al, ACS Chem. Biol. 2011, 6, 135–145).

As disclosed herein, variants of 9-40 Jant4-K₄₀ have been prepared to provide a further improved GLP-1 receptor antagonist. Peptide 9-40 Jant4-K₄₀ is acylated at position 40 by direct linkage of a C16 acyl group to the Lys side chain. Variants have been prepared inserting a spacer between the Lys side chain and the C16 acyl group. Table 2 presents the GLP-1 antagonist activity and solubility of these acylation variants.

Various amino acid substitutions were made to the primary sequence of 9-40Jant4-K₄₀ (DVSSYLEEQAVREFIAWLVKGGPSSGAPPPSK;SEQ ID NO: 3) and the GLP-1 antagonist activity and solubility of these variants is provided in Table 3.

Table 4 provides data regarding the effect of Aib substitutions on the activity and solubility of Jant4-K₄₀ (SEQ ID NO: 3) variants. Table 5 provides data regarding the effect of d-AA substitutions on the solubility of Jant4-K₄₀ (C16) (SEQ ID NO: 3) variants and Table 6 presents data regarding Trp substitution at position 3 of Jant4-K₄₀ (SEQ ID NO: 3).

Materials and Methods

Fmoc Synthesis

Peptides were prepared by automated Fmoc/t-Bu solid-phase methodology employing a Symphony peptide synthesizer (Peptide Technology, Tucson, AZ) starting with Wang resin (AAPptec, Louisville, KY) and 6-Cl-HOBt/DIC activation. All conventional residues were purchased from Midwest Biotech (Fisher, IN), 6-Cl- HOBt and DIC was obtained from AAPptec (Louisville, KY). Peptides were cleaved from the resin and de-protected by treatment with TFA containing 2.5% TIS, 2.5% H₂O, 1.5% methanol, 2.5% phenol, 0.5% DODT and 0.5% of dimethylsulfoxide. Peptide was precipitated with cold ethyl ether from a filtered TFA solution according to standard procedure. The fatty-acylation of peptides was performed on resin with tenfold excess of

Fmoc-Glu-OtBu/DEPBT/DIEA, repeated for double coupling, followed by tenfold excess of palmitic acid or another fatty acid/DEPBT/DIEA.

Antagonist Acylation

5 Palmitic acid was introduced to synthesized antagonist peptides using an orthogonal solid-phase protection scheme. Boc synthesis was utilized for peptide synthesis, allowing selective introduction of base-sensitive side-chain protected Lys(Fmoc)-OH at Lys40. The fully protected peptides were treated on resin with 20% piperidine in DMF (v/v) for 30 min to remove the Lys40 side-chain Fmoc group.

10 Amide bond formation was facilitated with excess fatty acid and 5 equiv of benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (Fluka) in DMF/DIEA (4:1 v/v) for approximately 18 h. Ninhydrin testing was used to monitor reaction progress, and acylation was confirmed after peptide cleavage by ESI mass spectrometry.

Peptide Purification

15 Reversed-phase HPLC (RP-HPLC) was used for peptide purification. A C18 stationary phase (Vydac 218TP, 250 mm _ 22 mm, 10 µm) was employed with a linear acetonitrile gradient in 0.1% trifluoroacetic acid during the preparative RP- HPLC purification. Analytical analysis was performed on peak fractions by employing RP-HPLC with a C8 column (Zorbax 300SB, 4.6 mm X 50 mm, 3.5 µm). Peptide identity and purity

20 was assessed by analytical RP-HPLC and ESI- or MALDI-mass spectrometry. All peptides were found to have the correct molecular weight and were approximately 95% pure. Lyophilized peptides were stored at 4 °C.

GLP-1 Receptor-Mediated cAMP Induction

25 The ability of peptides to stimulate or block cAMP induction at the GLP-1 receptor was examined by a luciferase-based reporter gene assay. Cotransfection of HEK 293 cells with the human GLP-1 receptor (Open Biosystems) and a cAMPinducible (cAMPresponsive element) luciferase gene constituted the cellular construct where receptor activation could be measured. Bioassays were performed by first serum depriving the cells for 16 h in 0.25% bovine growth serum (HyClone)- supplemented Dulbecco's

30 modified Eagle's medium (Invitrogen) and then adding serial dilutions of the peptides over the appropriate concentration ranges in 96-well poly-D-lysine-coated plates (BD Biosciences). For antagonism assays, a constant concentration of GLP-1 (0.05 nM) was added to the assay plate after the diluted peptides. Incubation continued for 5 h at 37 °C, 5% CO₂ and was followed by the addition of an equivalent volume (100 µL) of LucLite

35 luminescence substrate reagent

(Perkin-Elmer). MicroBeta 1450 liquid scintillation counting (Perkin-Elmer) quantified the luminescence signal in counts per second (cps) after shaking the plate at

600 rpm for 3 min. Data was plotted using Origin software (OriginLab) and the effective concentration 50 (EC₅₀) or inhibitory concentration 50 (IC₅₀) was determined by sigmoidal fitting. Potency was determined by comparative analysis of relative EC₅₀ or IC₅₀ values. Each experiment was repeated at least three times with each sample assayed in duplicate.

Animals

C57Bl/6 mice were obtained from Jackson Laboratories. Mice were single- or group-housed on a 12:12 h light-dark cycle at 22 °C with free access to food and water. All studies were approved by and performed according to the guidelines of the Institutional Animal Care and Use Committee of the University of Cincinnati.

Glucose Tolerance Test (GTT)

For the determination of glucose tolerance, mice were subjected to 6 h of fasting and injected intraperitoneally with glucose. Injections consisted of 1.5 g glucose per kg body weight (25% w/v D-glucose (Sigma) in 0.9% w/v saline). Tail blood glucose levels (mg dL⁻¹) were measured using a hand-held glucometer (FreeStyle Freedom Lite) before 0 min and at 15, 30, 60, and 120 min after injection.

Acute *In Vivo* Study

Mice received a subcutaneous injection of peptide (in PBS) either 1, 4, 8, 24, 48, 72, or 120 at varying doses before being challenged with an IP injection of dipeptidyl peptidase-IV-protected Ex-4 (0.65 nmol kg⁻¹). A GTT was performed fifteen minutes after the GLP-1 injection. Tail blood glucose values were obtained as described above.

Table 2: C16 Linker optimization/analysis on Jant 4-K₄₀ sequence (SEQ ID NO: 3)

#	9-40amide; Jant 4 K40[X]	IC ₅₀	Biactivity		Solubility [mg/mL] 80mM AmBicarb pH7.7
			SDV	N	
95	Free Amine	281	96	3	12.7
47	C16	14	7	15	6.1
52	γE-16	12	3	7	>20
53	γE ₂ -C16	13	5	10	>20
54	γE ₄ -C16	21	8	8	>20
55	γE ₆ -C16	22	15	5	>20
48	(miniPEG) ₂ γE-C16	9	4	7	9.0
56	MiniPEG-γE-C16	14	2	3	>20
57	gE-Mini(PEG) ₂ -gE-C16	9	7	5	>25
58	(mini)PEG ₂ -gE ₂ -16				>25
59	miniPEG-gE- miniPEG-gE-C16	11	7	5	>25
60	miniPEG-gE ₂ miniPEG-C16	5	2	5	>25
61	gE ₂ -(miniPEG) ₂ -C16	6	2	4	>25
62	gE-miniPEG-gE-C16 miniPEG-	7	3	4	>25
63	DiAcidC18	114	54	16	>25
64	gE ₂ -DiAcidC18	841	361	7	>25
65	gE ₄ -DiAcidC18	1071	624	8	>25
66	gE ₆ -DiAcidC18	1464	751	6	>25
67	(miniPEG) ₂ -gE- DiAcidC18	579	376	12	>25
68	miniPEG-gE DiAcidC18	718	130	3	>25

Table 3: Amino acid substitution variants of Jant4-K₄₀ (SEQ ID NO: 3)

#	9-40;Jant4	K40[C16]	Bioactivity			Solubility
			IC ₅₀	SDV	N	80mM AmeBicarb pH7.7
47		-amide	14	7	15	6.1
69	R28	-amide	16	1	3	13.7‡
70	E24, R28	-amide	14	4	4	>20
71	E17, R28	-amide	18	7	4	>20
72	E17,E24,R28	-amide	19	6	4	>20
73	R12, R28	-amide	27	17	4	<0.1
74	R12, E24,R28	-amide	15	3	4	>20
75	R12,E17,E24,R28	-amide	19	5	4	18.6
76	Exendin K40	-amide	6	1	3	18.6
77		R28 [§] -ACID	13	2	5	>20
78	E24, R28 [§] -ACID		19	13	13	>20
16	R12, E24, R28 [§] -ACID		18	12	13	>20
79	E24, R27	v28 [§] -ACID	115	37	10	>20
80	E24, R27	Aib28 [§] -ACID	106	1414		>20

[§] K40[miniPEG-gE-C16]

‡ Highly viscous solution

Table 4: Effect of Aib on activity & solubility of Jant4-K₄₀ (SEQ ID NO: 3)

#	9-40am; Jant4 k40[C16]	Bioactivity			Solubility	Solubility
		IC ₅₀	SDV	N	[mg/mL] 80mM AmBicarb pH7.7	[mg/mL] PBS pH7.7

81	Aib27	23	10	4	19.0 (6.1)	1.6
4328	K27, Aib28	13	13	10	18.9 (5.10)	0.2
82	K26, Aib	6	2	4	14.2 (6.0)	0.1
44	Aib26	8	1	4	19.0 (5.7)	0.1
83	Aib24	14	6	4	12.6 (4.2)	0.3
45	Aib19	8	2	4	11.1 (1.6)	0.4
46	Aib18	7	2	3	17.5 (3.5)	0.7
84	Aib16	30	13	3	5.2 (0.2)	0.2

Table 5: Improving solubility of Jant4-K₄₀ (C16) (SEQ ID NO: 3) with d-AA

#	9-40am; Jan54 K40[C16]	Bioactivity			Solubility [mg/mL] 80mM/AmBicarb pH7.7
		KC ₅₀	SDV	N	
49	<i>d-Glu</i> ₂₅	23	12	7	>20
85	<i>d-Glu</i> ₁₆	41	20	7	10.7
86	<i>d-Gln</i> ₁₇	41	24	6	2.2
50	<i>d-Val</i> ₁₉	124	86	6	>20
87	<i>d-Arg</i> ₂₀	16	6	4	0.8
88	<i>d-Glu</i> ₂₁	27	13	4	1.7
51	<i>d-HE</i> ₂₃	31	12	5	>20

Table 6: Trp substitution at position 3 of Jant4-K40 (SEQ ID NO: 3)

SEQ ID NO: #	Structure	IC50(nM)
89	Ex9-39amide, dK7(PEG2-γE(C16)), G8	6.2
90	Ex9-40amide, K40(C18 diacid)	28
91	Ex9-40amide, W11, K40(C18 diacid)	43
92	Ex9-40amide, dW11, K40(C18 diacid)	32
93	Ex9-40amide, W11, K40(mPeg-γE-C18 diacid)	87
94	Ex9-40amide, dW11, K40(mPeg-γE-C18 diacid)	115

EXAMPLE 2

Synthetic Procedure for MBX-1416:

The synthesis of MBX-1416 was conducted with a starting solid phase resin of Fmoc-Ser(tBu)-Wang at 0.1 mmol scale. The Fmoc-amino acids, that constitute residues 9 through 38 (Asp9-Pro38) were coupled to the free N-terminal amine sequentially once the first Fmoc-group was removed from the Fmoc-Ser(tBu)-Wang resin. An ABI peptide synthesizer was employed for automated assembly using standard Fmoc/DIC/Oxyma synthetic protocol as shown in the table below.

Details of Fmoc_DIC_Oxyma_0.10 mmol protocol used on the ABI433A Synthesizer

Coupling reagent		Fmoc protected amino acid	Solvents	Activation time	Coupling time	Deprotection
1M DIC in NMP (1.0 mL)	1M Oxyma in NMP(1.0mL)	1.0 mmol Cartridge	NMP and DCM	16 min	37 min	20% piperidine in DMF, 11 min

C18 diacid coupling procedure:

The N-terminal C18 diacid was coupled to the peptidyl resin once the full Asp9 through Ser39 peptide had been assembled. It was introduced as a tert-butyl protected C18 diacid (1 mmol) using DIC (1mmol) and Oxyma (1mmol) in DMF. The tert-butyl protected C18 diacid (1 mmol) and Oxyma (1 mmol) were dissolved in DMF (10 mL). To this mixture, DIC (1 mmol) was added and allowed to pre-activate for 10-15 min at room temperature. This reaction mixture was added to the Asp9- Ser39 peptidyl resin and the coupled proceeded with agitated for 4h at room temperature.

MBX-1416 Purification:

MBX-1416 was purified by a Waters HPLC controller 600 using a Gemini® 10µm C8 100 Å, LC 250X21.2 mm reverse-phase column (Cat. No 00G-4763-PO- AX) with a linear gradient from 80% A with 20%B to 20%A with 80% B, over 90 min at a flow rate of 15ml/min. The two buffers consisted of 0.1% TFA in 10% acetonitrile and 90% H2O (buffer A) and 0.1% TFA in 100% acetonitrile (buffer B).

CLAIMS

1. A GLP-1 receptor antagonist, said antagonist comprising the amino acid sequence of

R₁₀-DVX₁₁X₁₂YLX₁₅X₁₆QAX₁₉X₂₀EFX₂₃X₂₄WLVRRGGPSSGAPPPS-R₂₀ SEQ ID

NO: 97), wherein

R₁₀ is an C14-C20 fatty acid or diacid covalently linked to the N-terminal alpha amine of the GLP-1 antagonist amino acid sequence;

X₁₁ is Trp, dTrp or Ser;

X₁₂ is Arg, or Ser;

X₁₅ is Glu or dGlu;

X₁₆ is Glu, dGlu, Asp, homoglutamic acid or homocysteic acid;

X₁₉ is Val, cyclopropane, cyclopentane, cyclohexane or phenyl glycine;

X₂₀ is Arg, homolysine or citrulline;

X₂₃ is Ile, or dIle;

X₂₄ is Glu, or Ala; and

R₂₀ is COOH or CONH₂, optionally wherein 1, 2 or 3 amino acids at any of positions 16, 18, 19, 24, 26, or 28 are substituted with Aib, based on the numbering of native Exendin4 (SEQ ID NO: 1).

2. The GLP-1 antagonist of claim 1 wherein said antagonist comprises the amino acid sequence of

R₁₀-DVX₁₁X₁₂YLX₁₅X₁₆QAX₁₉X₂₀EFX₂₃EWLVRRGGPSSGAPPPS-R₂₀ SEQ ID NO:

99), wherein

R₁₀ is a C14-C20 fatty acid or diacid covalently linked to the N-terminal alpha amine of the GLP-1 antagonist amino acid sequence;

X₁₁ is Trp, dTrp or Ser; X₁₂ is Arg or Ser;

X₁₅ is Glu or dGlu;

X₁₆ is Glu, dGlu, Asp, homoglutamic acid or homocysteic acid;

X₁₉ is Val;

X₂₀ is Arg, homolysine or citrulline;

X₂₃ is Ile, or dIle; and

R₂₀ is COOH or CONH₂, optionally wherein 1, 2 or 3 amino acids at any of positions 16, 18, 19, 24, 26, or 28 are substituted with Aib, based on the numbering of native Exendin4 (SEQ ID NO: 1).

3. The GLP-1 antagonist of claim 1 or 2 wherein

R₁₀ is -CO(CH₂)₁₄₋₂₀CH₃ or -CO(CH₂)₁₄₋₂₀COOH;

X₁₁ is Trp, dTrp or Ser;

X₁₂ is Ser;

X₁₅ is Glu or dGlu;

X₁₆ is Glu, or dGlu;

X₁₉ is Val;

X₂₀ is Arg;

X₂₃ is Ile, or dIle; and

R₂₀ is COOH.

4. The GLP-1 antagonist of any one of claims 1-3 wherein R₁₀ is

-CO(CH₂)₁₆₋₁₈COOH covalently linked to the N-terminal alpha amine of the GLP-1 antagonist amino acid sequence.

5. A GLP-1 antagonist analog of any one of claims 1-4 wherein an amino

acid at position 16, 18, 19, 24, 26 or 28 is substituted with Aib, based on the numbering of native Exendin4 (SEQ ID NO: 1).

6. A GLP-1 antagonist analog of any one of claims 1-6 further comprising a

C-terminal extension of 1-3 amino acids, optionally wherein one of the amino acids of said C-terminal extension comprises an acylated amino acid, optionally an acylated Lys.

7. A GLP-1 receptor antagonist, said antagonist comprising the amino acid

sequence of

R₁₀-DX₁₀X₁₁X₁₂YLX₁₅X₁₆QAVREFX₂₃X₂₄WLVRGGPSSGAPPPS-R₂₀ (SEQ ID NO: 98); wherein

R₁₀ is an C14-C20 fatty acid or diacid covalently linked to the N- terminal alpha amine of the GLP-1 antagonist amino acid sequence;

X₁₀ is Trp, dTrp or Val;

X₁₁ is Trp, dTrp or Ser;

X₁₂ is Arg, Lys or Ser;

X₁₅ is Glu or dGlu;

X₁₆ is Trp, dTrp, dGlu or Glu;

X₂₃ is Ile or dIle;

X₂₄ is Ala or Glu; and

R₂₀ is COOH or CONH₂.

8. The GLP-1 receptor antagonist of claim 7 wherein
R₁₀ is -CO(CH₂)₁₄₋₂₀CH₃ or -CO(CH₂)₁₄₋₂₀COOH linked to the N-terminal alpha amine of the GLP-1 receptor antagonist;
X₁₀ is Trp, dTrp or Val;
X₁₁ is Trp, dTrp or Ser;
X₁₂ is Arg, Lys or Ser;
X₁₅ is Glu or dGlu;
X₁₆ is Trp, dTrp, dGlu or Glu;
X₂₃ is Ile or dIle; and
X₂₄ is Ala or Glu.
9. A GLP-1 receptor antagonist, said antagonist comprising the amino acid sequence of R₁₀-DVSSYLEEQAVREFIAWLKGGPSSGAPPPS-R₂₀ (SEQ ID NO: 3) or an amino acid sequence that differs from SEQ ID NO: 3 by 1, 2 or 3 amino acid substitutions while retaining GLP-1 agonist activity, wherein
R₁₀ is -CO(CH₂)₁₄₋₂₀CH₃ or -CO(CH₂)₁₄₋₂₀COOH linked to the N-terminal alpha amine of the GLP-1 receptor antagonist; and
R₂₀ is COOH or CONH₂.
10. The GLP-1 receptor antagonist of claim 9 wherein said GLP-1 receptor antagonist comprises one to three substitutions of Aib at any combination of positions 16, 18, 19, 24, 26 or 28, wherein said position number is relative to the native Exendin4 amino acid sequence.
11. The GLP-1 receptor antagonist of claim 9 or 10 wherein
R₁₀ is -CO(CH₂)₁₄₋₂₀COOH; and
R₂₀ is COOH.
12. The GLP-1 antagonist of any one of claims 7-11 wherein X₁₁ is Trp or dTrp.
13. The GLP-1 antagonist of any one of claims 7-12 wherein an amino acid at position 16, 18, 19, 24, 26 or 28 is substituted with Aib.

14. The GLP-1 antagonist of any one of claims 9-13 wherein
X₁₅ is dGlu;
X₁₆ is Glu; and
X₂₃ is Ile.
15. The GLP-1 antagonist of any one of claims 9-13 wherein
X₁₅ is Glu;
X₁₆ is Glu; and
X₂₃ is Ile.
16. The GLP-1 antagonist of any one of claims 9-15 further comprising a C-terminal extension of an amino acid having an acyl group linked to the side chain of the amino acid, optionally via a spacer.
17. The GLP-1 antagonist of claim 16 wherein said acylated amino acid is an acylated lysine.
18. The GLP-1 antagonist of claim 16 or 17 wherein the acyl group of the acylated amino acid is covalently linked to the amino acid side chain of the acylated amino acid via a spacer, optionally wherein the spacer comprises a
- i) gamma glutamic acid,
 - ii) minipeptide polymer: $-(\text{COCH}_2(\text{OCH}_2\text{CH}_2)_k\text{NH})-$, wherein k is 2, 4, 6 or 8,
 - iii) or any multiplicity or combination of i) and/or ii).
19. The GLP-1 antagonist of any one of claims 9-18 wherein R₂₀ is CONH₂.
20. A pharmaceutical composition comprising a GLP-1 antagonist of any one of claims 1-19 and a pharmaceutically acceptable carrier, diluent, or excipient.
21. A method of treating a patient suffering from atypical hypoglycemia said method comprising the step of administering to a patient in need thereof a pharmaceutical composition of claim 20 in an amount effective to elevate blood glucose levels.